Element Solutions (ESI) 10-Q 16 Nov 15 2015 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Sep. 30, 2015	Nov. 10, 2015
Document and Entity Information [Abstract]
Entity Registrant Name	Platform Specialty Products Corp
Document Type	10-Q
Current Fiscal Year End Date	--12-31
Entity Common Stock, Shares Outstanding (in shares)		210,879,597
Amendment Flag	false
Entity Central Index Key	1,590,714
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Well-known Seasoned Issuer	No
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2,015
Document Fiscal Period Focus	Q3

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Income Statement [Abstract]
Net sales	$ 597.3	$ 196.8	$ 1,807.3	$ 569.6
Cost of sales	354.6	93.6	1,088.8	285.5
Gross profit	242.7	103.2	718.5	284.1
Operating expenses:
Selling, technical, general and administrative	194.8	73.5	593.2	232.7
Research and development	16.6	6.4	47.8	18.5
Total operating expenses	211.4	79.9	641	251.2
Operating profit	31.3	23.3	77.5	32.9
Other (expense) income:
Interest expense, net	(52.7)	(8)	(143.2)	(23.4)
Loss on derivative contracts	(47.3)	(2.6)	(49.9)	(2.2)
Foreign exchange loss	(36.9)	(0.4)	(19.3)	(1.4)
Other income, net	1.4	0	19.8	0
Total other expense	(135.5)	(11)	(192.6)	(27)
(Loss) income before income taxes and non-controlling interests	(104.2)	12.3	(115.1)	5.9
Income tax (expense) benefit	(17.6)	1.6	(42)	3.6
Net (loss) income	(121.8)	13.9	(157.1)	9.5
Net income attributable to the non-controlling interests	(0.5)	(2)	(4)	(5.4)
Net (loss) income attributable to common stockholders	$ (122.3)	$ 11.9	$ (161.1)	$ 4.1
(Loss) earnings per share
Basic (in usd per share)	$ (0.58)	$ 0.09	$ (0.81)	$ 0.03
Diluted (in usd per share)	$ (0.58)	$ 0.08	$ (0.81)	$ 0.03
Weighted average shares outstanding
Basic (in Shares)	210.9	137.3	198.6	124.5
Diluted (in Shares)	210.9	152.7	198.6	140.5

Condensed Consolidated Stateme3

Condensed Consolidated Statements of Comprehensive Income (Loss) (Unaudited) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Statement of Comprehensive Income [Abstract]
Net (loss) income	$ (121.8)	$ 13.9	$ (157.1)	$ 9.5
Other comprehensive income (loss), before tax
Foreign currency translation adjustments	(350.2)	(60.3)	(614)	(37.3)
Pension and post-retirement plans
Net income recognized during the year	0	0	0	0.2
Pension and post-retirement plans	0	0	0	0.2
Tax expense	0	0	(0.5)	0
Pension and post-retirement plan, net of tax	0	0	(0.5)	0.2
Unrealized gain (loss) on available for sale securities
Unrealized gain (loss) on available for sale securities	1	(0.1)	1.2	(0.1)
Tax expense	0	0	0	0
Unrealized gain (loss) on available for sale securities, net of tax	1	(0.1)	1.2	(0.1)
Derivative financial instruments revaluation
Unrealized hedging loss arising during the period	(18.1)	0	(18.1)	(0.2)
Derivative financial instruments revaluation	(18.1)	0	(18.1)	(0.2)
Tax benefit	6.3	0	6.3	0.1
Derivative financial instruments revaluation, net of tax	(11.8)	0	(11.8)	(0.1)
Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]
Total other comprehensive loss, net of tax	(361)	(60.4)	(625.1)	(37.3)
Comprehensive loss	(482.8)	(46.5)	(782.2)	(27.8)
Comprehensive loss (income) attributable to the non-controlling interests	6.7	1.8	10.3	(2.9)
Comprehensive loss attributable to common stockholders	$ (476.1)	$ (44.7)	$ (771.9)	$ (30.7)

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Assets
Cash and cash equivalents	$ 682	$ 397.3
Restricted cash	0.3	600
Accounts receivable, net of allowance for doubtful accounts of $14.0 and $9.6 at September 30, 2015 and December 31, 2014, respectively	943.4	327.3
Inventories	466.9	205.8
Prepaid expenses and other current assets	220.1	46.1
Total current assets	2,312.7	1,576.5
Property, plant and equipment, net	266.9	178.6
Goodwill	2,842	1,405.3
Intangible assets, net	2,577.9	1,341.5
Other assets	76.3	45.4
Total assets	8,075.8	4,547.3
Liabilities & Stockholders' Equity
Revolving credit facilities	20	0
Accounts payable	386.1	106.7
Current installments of long-term debt and revolving credit facilities	36.1	13.2
Accrued income taxes payable	102.7	16.7
Accrued customer rebates and sales incentives	129	9.9
Financial guarantees and factoring	59	0
Other current liabilities	252.2	94.2
Total current liabilities	965.1	240.7
Long-term debt and capital lease obligations	3,401.4	1,392.4
Long-term retirement benefits, less current portion	44.2	38.8
Long-term deferred income taxes	567.1	202.3
Long-term contingent consideration	70.2	63.9
Other long-term liabilities	113.6	56.6
Total liabilities	$ 5,161.6	$ 1,994.7
Commitments and contingencies (Note 15)
Redeemable preferred stock - Series B	$ 645.9	$ 0
Stockholders' Equity
Preferred stock - Series A	0	0
Common stock, $0.01 par value per share (effective January 23, 2014), 400,000,000 shares authorized, 210,879,597 and 182,066,980 shares issued and outstanding at September 30, 2015 and December 31, 2014, respectively	2.1	1.9
Additional paid-in capital	3,287.3	2,812.4
Accumulated deficit	(385.2)	(224.1)
Accumulated other comprehensive loss	(741.4)	(130.6)
Total stockholders' equity	2,162.8	2,459.6
Non-controlling interests	105.5	93
Total equity	2,268.3	2,552.6
Total liabilities, redeemable preferred shares and equity	$ 8,075.8	$ 4,547.3

Condensed Consolidated Balance5

Condensed Consolidated Balance Sheets (Unaudited) (Parentheticals) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts (in Dollars)	$ 14	$ 9.6
Common shares, par value (in usd per share)	$ 0.01	$ 0.01
Common shares authorized (in shares)	400,000,000	400,000,000
Common shares issued (in shares)	210,879,597	182,066,980
Common shares outstanding (in shares)	210,879,597	182,066,980

Condensed Consolidated Stateme6

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Millions	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Net Cash Provided by (Used in) Operating Activities [Abstract]
Net cash flows provided by operating activities	$ 131.1	$ 79.5
Cash flows from investing activities:
Change in restricted cash	599.7	(315)
Capital expenditures	(32.1)	(7.3)
Investment in registrations of products	(26.2)	0
Proceeds from disposal of property, plant and equipment	12.1	0.5
Acquisition of businesses, net	(2,857.9)	(59)
Other, net	(1.4)	0
Net cash flows used in investing activities	(2,305.8)	(380.8)
Cash flows from financing activities:
Proceeds from issuance of debt, net of discount and premium	2,085.6	0
Change in revolving credit facilities, net	4.7	0
Repayments of borrowings	(15.5)	(5.8)
Proceeds from issuance of common stock, net	469.5	473.4
Payment of debt financing fees	(45.5)	(4.1)
Change in factored liabilities	(16.8)	0
Other, net	(1)	0.1
Net cash flows provided by financing activities	2,481	463.6
Effect of exchange rate changes on cash and cash equivalents	(21.6)	(3.6)
Net increase in cash and cash equivalents	284.7	158.7
Cash and cash equivalents at beginning of period	397.3	123
Cash and cash equivalents at end of period	682	281.7
Noncash Investing Activities
Unpaid capital expenditures included in accounts payable and accrued expenses	$ 3.5	$ 5.8

Condensed Consolidated Stateme7

Condensed Consolidated Statements of Changes in Stockholders' Equity Statement - USD ($) $ in Millions	Total	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]	Parent [Member]	Noncontrolling Interest [Member]	Exchange of Warrants [Member]	Exchange of Warrants [Member]Common Stock [Member]	Exchange of Warrants [Member]Additional Paid-in Capital [Member]	Exchange of Warrants [Member]Parent [Member]	United States Postretirement Benefit Plan of US Entity [Member]	United States Postretirement Benefit Plan of US Entity [Member]Common Stock [Member]	United States Postretirement Benefit Plan of US Entity [Member]Additional Paid-in Capital [Member]	United States Postretirement Benefit Plan of US Entity [Member]Parent [Member]	IPO [Member]	IPO [Member]Common Stock [Member]	IPO [Member]Additional Paid-in Capital [Member]	IPO [Member]Parent [Member]
Beginning balance, shares (in Shares) at Dec. 31, 2013		2,000,000	103,571,941
Beginning balance, stockholders' equity at Dec. 31, 2013	$ 1,115.1	$ 0	$ 0	$ 1,212	$ (194.2)	$ 1.3	$ 1,019.1	$ 96
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(5.9)				(7.4)		(7.4)	1.5
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	3.4		0	0	0	3.4	3.4	0
Issuance of common stock to former non-founder director for exercise of stock options		$ 0	$ 1	(1)
Issuance of stock, shares (in Shares)			3,959
Issuance of stock	0			0			0
Exercise of warrants for common shares (in shares)										14,992,950
Exercise of warrants for common shares									$ 172.5	$ 0.2	$ 172.3	$ 172.5
Issuance of common shares with 401 (k) (in shares)														1,670,386
Issuance of common shares with 401 (k)													$ 18.4	$ 0	$ 18.4	$ 18.4
Distribution to non-controlling interest	(0.2)							(0.2)
Ending balance, shares (in Shares) at Mar. 31, 2014		2,000,000	120,239,236
Ending balance, stockholders' equity at Mar. 31, 2014	1,303.3	$ 0	$ 1.2	1,401.7	(201.6)	4.7	1,206	97.3
Beginning balance, shares (in Shares) at Dec. 31, 2013		2,000,000	103,571,941
Beginning balance, stockholders' equity at Dec. 31, 2013	1,115.1	$ 0	$ 0	1,212	(194.2)	1.3	1,019.1	96
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	9.5
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	(37.3)
Ending balance, shares (in Shares) at Sep. 30, 2014		2,000,000	137,304,330
Ending balance, stockholders' equity at Sep. 30, 2014	$ 1,579.6	$ 0	$ 1.4	1,703.4	(190.1)	(33.5)	1,481.2	98.4
Price of shares issued (in usd per share)	$ 11								$ 11.50
Beginning balance, shares (in Shares) at Mar. 31, 2014		2,000,000	120,239,236
Beginning balance, stockholders' equity at Mar. 31, 2014	$ 1,303.3	$ 0	$ 1.2	1,401.7	(201.6)	4.7	1,206	97.3
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	1.5				(0.4)		(0.4)	1.9
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	19.7					18.4	18.4	1.3
Issuance of stock, shares (in Shares)			15,800,000
Issuance of stock	300.2		$ 0.2	300			300.2
Exercise of warrants for common shares (in shares)										1,251,744
Exercise of warrants for common shares	(13.4)			(13.4)	0	0	(13.4)	0	$ 14.4	$ 0	14.4	14.4
Recovery of short swing profits, net	0.5			0.5	0	0	0.5	0
Equity compensation expense	0.3			0.3	0	0	0.3	0
Distribution to non-controlling interest	(0.2)							(0.2)
Ending balance, shares (in Shares) at Jun. 30, 2014		2,000,000	137,290,980
Ending balance, stockholders' equity at Jun. 30, 2014	$ 1,626.3	$ 0	$ 1.4	1,703.5	(202)	23.1	1,526	100.3
Price of shares issued (in usd per share)	$ 19								$ 11.50
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	$ 13.9				11.9		11.9	2
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	(60.4)					(56.6)	(56.6)	(3.8)
Issuance of stock	(0.4)			(0.4)			(0.4)
Exercise of warrants for common shares (in shares)			9,242							4,108
Exercise of warrants for common shares									$ 0.1	$ 0	0.1	0.1
Equity compensation expense	0.2			0.2	0	0	0.2	0
Distribution to non-controlling interest	(0.1)							(0.1)
Ending balance, shares (in Shares) at Sep. 30, 2014		2,000,000	137,304,330
Ending balance, stockholders' equity at Sep. 30, 2014	1,579.6	$ 0	$ 1.4	1,703.4	(190.1)	(33.5)	1,481.2	98.4
Beginning balance, shares (in Shares) at Dec. 31, 2014		2,000,000	182,066,980
Beginning balance, stockholders' equity at Dec. 31, 2014	2,552.6	$ 0	$ 1.9	2,812.4	(224.1)	(130.6)	2,459.6	93
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(26.2)				(26.6)		(26.6)	0.4
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	(425.9)					(417.2)	(417.2)	(8.7)
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14			10,050,290
Issuance of common stock to former non-founder director for exercise of stock options		$ 0	$ 0	0.9
Issuance of common shares to directors for exercise of stock options, value	0.9						0.9	0
Issuance of common shares to directors for exercise of stock options (in shares)			75,000
Issuance of stock, shares (in Shares)			21,316
Issuance of stock	0			0.2			0.2	(0.2)
Exercise of warrants for common shares (in shares)										7,986
Exercise of warrants for common shares									0.1	$ 0	0.1	0.1
Issuance of common shares with 401 (k) (in shares)														0
Issuance of common shares with 401 (k)													0.7	$ 0	0.7	0.7
Acquisition of non-controlling interest with Arysta Acquisition	24.6							24.6
Ending balance, shares (in Shares) at Mar. 31, 2015		2,000,000	192,221,572
Ending balance, stockholders' equity at Mar. 31, 2015	2,126.8	$ 0	$ 1.9	2,814.3	(250.7)	(547.8)	2,017.7	109.1
Beginning balance, shares (in Shares) at Dec. 31, 2014		2,000,000	182,066,980
Beginning balance, stockholders' equity at Dec. 31, 2014	2,552.6	$ 0	$ 1.9	2,812.4	(224.1)	(130.6)	2,459.6	93
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(157.1)
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	$ (625.1)
Issuance of common shares to directors for exercise of stock options (in shares)	75,000
Ending balance, shares (in Shares) at Sep. 30, 2015		2,000,000	210,879,597
Ending balance, stockholders' equity at Sep. 30, 2015	$ 2,268.3	$ 0	$ 2.1	3,287.3	(385.2)	(741.4)	2,162.8	105.5
Beginning balance, shares (in Shares) at Mar. 31, 2015		2,000,000	192,221,572
Beginning balance, stockholders' equity at Mar. 31, 2015	2,126.8	$ 0	$ 1.9	2,814.3	(250.7)	(547.8)	2,017.7	109.1
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	(9.1)				(12.2)		(12.2)	3.1
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	161.8					160.2	160.2	1.6
Issuance of stock, shares (in Shares)			406,217															18,226,414
Issuance of stock	0			4.7			4.7	(4.7)									$ 483	$ 0.2	$ 482.8	$ 483
Exercise of warrants for common shares (in shares)										6,841
Exercise of warrants for common shares	(14.8)			(14.8)	0	0	(14.8)	0	0.3	$ 0	0.3	0.3
Issuance of common shares with 401 (k)													0.6		0.6	0.6
Ending balance, shares (in Shares) at Jun. 30, 2015		2,000,000	210,861,044
Ending balance, stockholders' equity at Jun. 30, 2015	$ 2,748.6	$ 0	$ 2.1	3,287.9	(262.9)	(387.6)	2,639.5	109.1
Price of shares issued (in usd per share)	$ 26.50
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net (loss) income	$ (121.8)				(122.3)		(122.3)	0.5
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14	(361)					(353.8)	(353.8)	(7.2)
Issuance of common shares to directors for exercise of stock options (in shares)			2,500
Issuance of stock, shares (in Shares)			6,343
Exercise of warrants for common shares (in shares)										9,710
Exercise of warrants for common shares									$ 0.1	$ 0	$ 0.1	$ 0.1
Issuance of common shares with 401 (k)													$ (0.7)		$ (0.7)	$ (0.7)
Acquisition of non-controlling interest with Arysta Acquisition	6.4							6.4
Acquisition of remaining interest in Arysta Colombia	(3.3)							(3.3)
Ending balance, shares (in Shares) at Sep. 30, 2015		2,000,000	210,879,597
Ending balance, stockholders' equity at Sep. 30, 2015	$ 2,268.3	$ 0	$ 2.1	$ 3,287.3	$ (385.2)	$ (741.4)	$ 2,162.8	$ 105.5

Basis of Presentation and Signi

Basis of Presentation and Significant Accounting Policies	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation and Significant Accounting Policies	BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES Platform Specialty Products Corporation is a global, diversified producer of high-technology specialty chemical products. The Company's business involves the formulation of a broad range of solutions-oriented specialty chemicals, which are sold into multiple industries, including agrochemical, animal health, electronics, graphic arts, plating, and offshore oil production and drilling. The Company refers to its products as “dynamic chemistries” due to their intricate chemical compositions. As further described in Note 20, Segment Information, the Company operates in two segments: Performance Applications and Agricultural Solutions. Platform was originally incorporated with limited liability under the laws of the British Virgin Islands under the BVI Companies Act on April 23, 2013. Until the MacDermid Acquisition on October 31, 2013, as described below, the Company had neither engaged in any operations nor generated any income. On October 31, 2013, the Company completed the MacDermid Acquisition pursuant to which it indirectly acquired substantially all of the equity of MacDermid Holdings, which, at the time, owned approximately 97% of MacDermid. The Company acquired the remaining 3% of MacDermid on March 4, 2014, pursuant to the terms of the Exchange Agreement. On January 22, 2014, the Company completed its Domestication and on January 23, 2014, the Company's common stock, par value $0.01 per share, began trading on the NYSE under the ticker symbol “PAH.” Basis of Presentation These unaudited interim Condensed Consolidated Financial Statements and related information have been prepared in accordance with U.S. GAAP for interim financial information and in accordance with the applicable rules and regulations of the SEC. Accordingly, they do not include all of the disclosures required in connection with annual financial statements. These unaudited interim Condensed Consolidated Financial Statements reflect all adjustments that are, in the opinion of management, normal, recurring and necessary for a fair statement of the results of operations. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes thereto included in the Company’s Annual Report. The year-end Condensed Consolidated Balance Sheet data was derived from audited financial statements, but does not include all footnote disclosures from the annual financial statements. Principles of Consolidation The accompanying unaudited interim Condensed Consolidated Financial Statements include Platform's accounts and all of its controlled subsidiaries. All subsidiaries are included in the unaudited interim Condensed Consolidated Financial Statements for the entire period or, if acquired, from the date that the Company obtains control. The Company fully consolidates the income, expenses, assets, liabilities and cash flows of subsidiaries from the date it acquires control up to the date control ceases. All intercompany accounts and transactions were eliminated in consolidation. Significant Accounting Policies Equity Securities Equity securities that have a readily determinable fair value are classified as available for sale and are carried at fair value. Unrealized holding gains and losses are recorded in other comprehensive income. Equity securities which do not have readily determinable fair values are recorded at cost and are evaluated whenever events or changes in circumstances indicate that the carrying values of such investments may be impaired. Financial Guarantees and Factoring of Accounts Receivable Guarantees provided to financial institutions on vendor and customer loans used to settle outstanding accounts receivable balances are recorded as liabilities until such time when the guarantee periods have elapsed, at which time the accounts receivable balances and the related financial guarantees are reversed. Factoring arrangements, where substantially all economic risks and rewards associated with trade receivables are transferred to a third party, are accounted for by derecognizing the trade receivables upon receipt of cash proceeds from the factoring arrangement. Factoring arrangements, whereby some, but not substantially all, economic risks and rewards are transfered to a third party and the assets subject to the factoring arrangement remain under the Company's control are accounted for by not derecognizing the trade receivables and recognizing any related obligations to the third party. Product Registrations Product registrations represent external costs incurred to obtain distribution rights from regulatory bodies for certain products in our Agricultural Solutions segment. These costs include laboratory testing, legal, regulatory filing and other costs. Only costs associated with products that are probable of generating future cash flows are capitalized. The capitalized costs are amortized over the useful life of the registrations and are included in "Selling, technical, general and administrative" expenses in the Condensed Consolidated Statement of Operations and are evaluated for impairment in the same manner as other finite-lived intangible assets. Equity Method Investments Investments over which the Company has the ability to exercise significant influence, but which the Company does not control, are accounted for under the equity method of accounting and are included in "other assets" on the Condensed Consolidated Balance Sheet. Significant influence generally exists when the Company holds between 20% and 50% of the voting power of another entity. Investments are initially recognized at cost. The Condensed Consolidated Financial Statements include the Company's share of net earnings or losses from the date that significant influence commences until the date that significant influence ceases. When the Company's share of losses exceeds its interest in an equity investment, the carrying amount of that interest is reduced to zero, and the recognition of further losses is discontinued, except to the extent that the Company has an obligation or has made payments on behalf of the investee. Revenue Recognition The Company recognizes revenue, including freight charged to customers, net of applicable rebates, estimates for sales returns and allowances and discounts, when the earnings process is complete. This occurs when products have been shipped to or received by the customer, in accordance with the terms of the agreement by and between the Company and such customer, title and risk of loss has been transferred, pricing is fixed or determinable and collectability is reasonably assured. The Company allows certain distributors within the Agricultural Solutions segment one-time, non-repeatable extensions of credit on a limited portion of purchases made during a purchasing cycle, which remain in the distributor’s inventory. The extension of credit is not a right to return, and distributors must pay unconditionally when the extended credit period expires. Accounting Policies Recently Adopted and Pending Pronouncements Business Combinations (Topic 805) - In September 2015, the FASB issued ASU No. 2015-16 “Simplifying the Accounting for Measurement-Period Adjustments.” Under the updated guidance, an entity is no longer required to retrospectively apply adjustments to provisional amounts recorded as a part of a business combination. Adjustments to provisional amounts identified during the measurement period continue to be calculated as of the acquisition date but are recognized in the period in which they are determined, including the effects of such adjustments on earnings. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company adopted this ASU as of September 30, 2015. This ASU may have a material impact on the Company's future financial statements if material measurement period adjustments are recorded. Revenue from Contracts with Customers (Topic 606) - In August 2015, the FASB issued ASU No. 2015-14 “Deferral of the Effective Date,” which defers the effective date of ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)," for all entities by one year. As a result, the provisions of ASU No. 2014-09 will be effective prospectively for fiscal years and interim periods beginning after December 15, 2017. ASU No. 2014-09 (1) removes inconsistencies and weaknesses in revenue requirements, (2) provides a more robust framework for addressing revenue issues, (3) improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, (4) provides more useful information to users of financial statements through improved disclosure requirements, and (5) simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company continues to evaluate the impact of ASU 2014-09. Inventory (Topic 330) - In July 2015, the FASB issued ASU No. 2015-11, “ Simplifying the Measurement of Inventory.” Under the updated guidance, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business, less predictable costs of completion, disposal, and transportation. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2016, with early adoption permitted. The Company adopted this ASU as of October 1, 2015 by replacing its lower of cost or market test with a lower of cost and net realizable value test. This ASU did not have a material impact on the Company's financial statements. Fair Value Measurement (Topic 820) - In May 2015, the FASB issued ASU No. 2015-07, “ Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent).” This update eliminates diversity in practice related to investments whose fair value is measured using net asset values as a practical expedient, and removes the requirement to categorize such investments within the fair value hierarchy. The guidance is effective retrospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company continues to evaluate the impact of this new ASU, which is not expected to have a material impact on its financial statements. Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40 ) - In April 2015, the FASB issued ASU No. 2015-05, “ Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.” This update provides explicit guidance to customers utilizing a cloud computing solution to help determine whether such an arrangement includes a software license, in which case the accounting applied would be similar to that of other software license arrangements. Otherwise, the arrangement would be accounted for as a service contract. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company does not expect this ASU to have a material impact on its financial statements. Interest - Imputation of Interest (Subtopic 835-30) - In April 2015, the FASB issued ASU No. 2015-03, “ Simplifying the Presentation of Debt Issuance Costs.” This update eliminates the difference in the presentation of debt issuance costs and debt discount and premiums by requiring that debt issuance costs be presented as deductions from the carrying value of the related debt, in a manner similar to debt discounts. The guidance is effective retroactively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company early adopted this ASU, and reclassified approximately $10.3 million of debt issuance costs related to term debt from assets to contra-liabilities as of December 31, 2014. Derivatives and Hedging (Topic 815) - In November 2014, the FASB issued ASU No. 2014-16, “ Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force).” Under current practice, there were predominantly two methods used to evaluate whether the nature of the host contract in a hybrid financial instrument is more akin to debt or equity: one considered all the features including the embedded and the other excluded the embedded derivative in the consideration. This update eliminates the difference in practice by clarifying that the evaluation should be based on all the instrument’s features, including the embedded derivative, and that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. The guidance is effective for fiscal years and interim periods beginning after December 15, 2015 and is applied in a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of our fiscal year 2016. Early adoption, including in an interim period, is permitted. The Company adopted the provision of this ASU during the first quarter of 2015, with the issuance of the Series B Convertible Preferred Stock. This ASU did not have a material impact on the Company's financial statements, as there were no hybrid financial instruments requiring retrospective application. Out of Period Adjustment In connection with the preparation of the Company's unaudited interim Condensed Consolidated Financial Statements for the period ended June 30, 2015, the Company identified a prior period error related to foreign currency accounting within Arysta and purchase accounting for the Arysta Acquisition in accordance with ASC 805 - Business Combinations for the period ended March 31, 2015. The Company determined that goodwill was understated and foreign currency translation adjustment loss was overstated by approximately $73.0 million . Based on an analysis of qualitative and quantitative factors, management has concluded that this error was not material to the Company's unaudited interim Condensed Consolidated Financial Statements for the period ended March 31, 2015 or June 30, 2015. As a result, the affected balances were corrected in the unaudited interim Condensed Consolidated Financial Statements for the period ended June 30, 2015. Reclassifications Certain prior year amounts have been reclassified to conform to the current period’s presentation, including approximately $10.3 million of debt issuance costs related to term debt from assets to contra-liabilities as of December 31, 2014 as a result of early adopting ASU 2015-15, “ Simplifying the Presentation of Debt Issuance Costs."

Acquisitions of Businesses

Acquisitions of Businesses	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Acquisitions of Businesses	ACQUISITIONS OF BUSINESSES Arysta Acquisition On February 13, 2015, Platform completed the Arysta Acquisition for approximately $3.50 billion , consisting of $2.86 billion in cash (net of acquired cash, closing adjustments and including Seller transaction expenses paid by Platform) and the issuance to the Seller of $600 million of Platform’s Series B Convertible Preferred Stock with a fair market value of $646 million . The Company acquired Arysta to expand its presence in the agrochemical business, complementing our acquisitions of Agriphar and CAS. Arysta provides products and solutions utilizing globally managed patented, proprietary off-patent agrochemical AIs and biological solutions, or biosolutions, and off-patent agrochemical offerings. Biosolutions includes biological stimulants, or biostimulants, innovative nutrition and biological control, or biocontrol, products. Arysta is included in the Company's Agricultural Solutions business segment. In connection with the Arysta Acquisition, the Company incurred $4.4 million and $32.2 million in related expenses for the three and nine months ended September 30, 2015 , respectively, which are included in “Selling, technical, general and administrative expenses” in the Condensed Consolidated Statement of Operations and $6.4 million in related expenses through December 31, 2014. CAS Acquisition On November 3, 2014, Platform completed the CAS Acquisition for approximately $1.04 billion , consisting of $983 million in cash, net of acquired cash and certain post-closing working capital and other adjustments, and 2,000,000 shares of Platform common stock. Due to regulatory constraints, title to certain CAS businesses located in Russia was not transferred to Platform until the first quarter of 2015. In connection with the CAS Acquisition, the Company entered into six supply agreements with Chemtura to supply certain products to the Company, on an exclusive basis. These arrangements included capital leases for certain equipment totaling $13.2 million , which were recorded as of June 30, 2015. This measurement period adjustment had a cumulative impact to depreciation of $2.2 million , which was recorded in the three months ended June 30, 2015 as the impact on the three months ended March 31, 2015 and the year ended December 31, 2014 was not material. In addition, the Company has agreed to fund the asset retirement obligations associated with the related equipment and accordingly, the Company has recognized an asset retirement obligation of $13.2 million . The supply agreements, which will remain in force until either party provides advance termination notice, have a minimum term of four years from the date of the CAS Acquisition. In line with Platform's business strategy of growing into niche markets and applications, the Company acquired CAS to enter the agrochemical industry. CAS is a niche provider of seed treatments and crop protection applications in numerous geographies across seven major product lines - adjuvants, fungicides, herbicides, insecticide, miticides, plant growth regulators and seed treatments. CAS is included in the Company's Agricultural Solutions business segment. In connection with the CAS Acquisition, the Company incurred $1.7 million and $11.5 million in related expenses for the three and nine months ended September 30, 2015 , respectively, which are included in “Selling, technical, general and administrative expenses” in the Condensed Consolidated Statement of Operations and $33.9 million in related expenses through December 31, 2014. Agriphar Acquisition On October 1, 2014, Platform completed the Agriphar Acquisition for a purchase price of approximately €300 million ( $370 million ), consisting of $350 million in cash, net of acquired cash and certain post-closing working capital and other adjustments, and 711,551 restricted shares of our common stock. Such restricted shares will become unrestricted beginning January 2, 2018, unless agreed otherwise in accordance with the terms of the acquisition agreement. The agreement also stipulates that prior to January 2, 2018, the seller may transfer (i) a maximum of 1/3 of its shares as of January 2, 2016, (ii) 1/3 of its shares as of January 2, 2017 and (iii) 1/3 of its shares as of January 2, 2018, in each case subject to the terms and provisions of a solvency letter described in the acquisition agreement. Additionally, the seller was granted a put option to sell and transfer all (but not part) of its shares, on (but not prior to) the date that is six months from the closing of the Agriphar Acquisition, which option was not exercised. As a result, for the period ended March 31, 2015, the value of the option totaling $3.0 million was reversed and included in "Other income (expense), net" in the Condensed Consolidated Statement of Operations. The Company acquired Agriphar in its crop protection vertical as it believes Agriphar’s and CAS’ businesses are very complementary in terms of product range and distribution capabilities. Agriphar is a European crop protection group supported by a team of researchers and regulatory experts which provides a wide range of fungicides, herbicides and insecticides with end markets primarily across Europe. Agriphar is included in the Company's Agricultural Solutions business segment. In connection with the Agriphar Acquisition, the Company incurred $0.1 million and $0.9 million in related expenses for the three and nine months ended September 30, 2015 , respectively, which are included in “Selling, technical, general and administrative expenses” in the Condensed Consolidated Statement of Operations and $4.2 million in related expenses through December 31, 2014. Acquisition Revenues and Net Income (Loss) Revenues contributed by the Arysta, CAS and Agriphar Acquisitions for the three and nine months ended September 30, 2015 were as follows: (amounts in millions) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Arysta $ 318.2 $ 837.6 CAS 73.8 282.4 Agriphar 25.6 145.6 Total $ 417.6 $ 1,265.6 As the integration of the Arysta, CAS and Agriphar Acquisitions continues, discrete revenues reported by our existing businesses are being effected by the integration process and are becoming less comparable to prior periods. The Arysta, CAS and Agriphar Acquisitions had net (loss) income for the three and nine months ended September 30, 2015 as follows: (amounts in millions) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Arysta $ (34.8 ) $ (100.6 ) CAS (25.0 ) (52.5 ) Agriphar 3.3 25.7 Total $ (56.5 ) $ (127.4 ) Purchase Price Allocation The following table summarizes the consideration transferred and transaction related costs incurred to acquire Arysta, CAS and Agriphar and the applicable amounts of identified assets acquired and liabilities assumed at the acquisition date: (amounts in millions) Arysta CAS Agriphar Consideration Cash, net $ 2,856.2 $ 983.1 $ 350.2 Equity Instruments 645.9 52.0 16.6 Derivative liability — — 3.5 Total Consideration $ 3,502.1 $ 1,035.1 $ 370.3 Transaction related costs $ 38.6 $ 45.4 $ 5.1 Identifiable Assets acquired and Liabilities Assumed Accounts receivable $ 674.5 $ 154.2 $ 60.1 Inventories 295.7 132.1 42.7 Other current assets 132.2 19.1 0.4 Property, plant and equipment 110.0 24.8 31.7 Identifiable intangible assets 1,638.9 534.0 183.0 Other assets 38.2 11.4 4.5 Current Liabilities (574.0 ) (69.7 ) (47.5 ) Non-current deferred tax liability (488.5 ) (26.7 ) (64.9 ) Other long term liabilities (74.2 ) (13.4 ) (9.0 ) Non-controlling interest (31.0 ) — — Total identifiable net assets 1,721.8 765.8 201.0 Goodwill 1,780.3 269.3 169.3 Total purchase price $ 3,502.1 $ 1,035.1 $ 370.3 The purchase accounting and purchase price allocation for the Arysta Acquisition has not been finalized as of the date of this filing pending finalization of fair values assigned to identifiable intangible assets and non-controlling interest, as well as accounts receivable, inventory and reserves related to legal matters and environmental exposure. The purchase price allocation was updated to reflect current estimated fair values at the acquisition date of accounts receivable, inventories, sales allowances and non-controlling interest, with corresponding adjustments reflected in goodwill. Purchase accounting and purchase price allocation is complete for the Agriphar Acquisition, and substantially complete for the CAS Acquisition, with the exception of valuations related to the supply agreements with Chemtura described above. As a part of the CAS Acquisition, the Company paid for a 15% equity interest in Certis Europe B.V. that was transferred during the second quarter of 2015 after receiving approval from the shareholders of Certis Europe B.V., who had certain rights of first refusal with respect to such transfer of shares. The Company completed the valuation of Certis Europe B.V. during the quarter ended September, 30, 2015, and accordingly reduced the preliminary estimate of its equity interest by $10.1 million to $5.0 million , with a corresponding adjustment reflected in goodwill. The value of this equity interest is classified in other assets. The excess of the respective cost of the Acquisitions over the net of amounts assigned to the fair values of the assets acquired and the liabilities assumed is recorded as goodwill and represents the value of estimated synergies and the assembled workforces resulting from the Acquisitions. Of the $2.22 billion of goodwill recorded in connection with the Arysta, CAS and Agriphar Acquisitions, $185 million is expected to be deductible for tax purposes as result of the CAS Acquisition. Identifiable intangible assets recorded in conjunction with the Arysta Acquisition have been assigned the following estimated useful lives: 20 years for customer lists, average of 12 years for developed technology and indefinite for tradenames. Pro Forma Revenue and Earnings The following unaudited pro forma summary presents consolidated information of the Company for the three and nine months ended September 30, 2015 and 2014 , as if the Arysta Acquisition had occurred on January 1, 2014, excluding CAS and Agriphar from the 2014 results as these Acquisitions closed prior to 2015: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Revenue $ 597.3 $ 557.9 $ 1,894.7 $ 1,638.5 Net loss attributable to stockholders $ (118.6 ) $ (18.5 ) $ (160.1 ) $ (130.5 ) For the three and nine months ended September 30, 2015 , the Company incurred $4.4 million and $32.2 million , respectively, of acquisition-related expenses which have been reflected in the pro forma earnings above, net of tax, as if they had been incurred in 2014. These pro forma amounts have been prepared to reflect fair value adjustments to intangible assets and the related amortization expense, net of tax, from January 1, 2014, as well as the effect of the debt instruments used to fund the Arysta Acquisition. First Closing of OMG Acquisition On May 31, 2015, the Company entered into a merger agreement with OMG and Apollo and a purchase and separation agreement with Apollo pursuant to which Apollo agreed to first acquire OMG in its entirety, and then subsequently sell to Platform the OMG Businesses. On October 28, 2015, the Company completed the acquisition of the OMG Businesses, other than their Malaysian subsidiary, pursuant to the terms and conditions set forth in the merger agreement. This transaction is the first closing of the Company's two-stage acquisition of the OMG Businesses for a total purchase price of approximately $367 million , subject to purchase price adjustments. The Company expects to complete its acquisition of the Malaysian subsidiary during the first quarter of 2016, subject to customary closing conditions, including the absence of a material adverse effect with respect to the Malaysian subsidiary. Platform believes the OMG Acquisition is in line with its business strategy of growing into niche markets. The OMG Businesses will be included in the Company's Performance Applications business segment. OMG’s Electronic Chemicals business is similar to Platform's legacy MacDermid electronic chemical and surface treatment businesses by developing, producing and supplying chemicals for electronic and industrial applications. OMG’s Photomasks products are used by customers to produce semiconductors and related products. Proposed Alent Acquisition On July 13, 2015, Platform and Alent issued an announcement, pursuant to Rule 2.7 of the U.K. Takeover Code, disclosing the terms of a recommended offer by MacDermid Performance Acquisitions Ltd., a private limited company registered in England and Wales, and an indirect subsidiary of Platform, to acquire all of the shares of Alent. The Alent Acquisition will be completed pursuant to the Scheme. In connection with the Alent Acquisition, on July 13, 2015, (i) Platform, MacDermid Performance Acquisitions Ltd., and Alent entered into a co-operation agreement and (ii) Platform, certain subsidiary guarantors, Credit Suisse AG and certain other Credit Suisse AG affiliates entered into a $1.88 billion interim facility letter. Pursuant to the terms of the Alent Acquisition, each shareholder of Alent is entitled to receive 503 pence in cash for each ordinary share of Alent. The Scheme includes a partial share alternative under which eligible shareholders of Alent can elect to receive Platform common stock in lieu of part or all of the cash consideration that they would otherwise be entitled to receive in exchange for their Alent Shares on the basis of 0.31523 new Platform shares for every Alent share. Such alternative is to be limited to the issue of new Platform shares in respect of approximately 21.9% of Alent’s issued share capital at close of business on July 10, 2015. The Alent Acquisition values Alent’s entire share capital at approximately £1.35 billion ( $2.10 billion , based on the GBP/USD exchange rate of 1.5517 on July 10, 2015). On the date of the Rule 2.7 announcement, and as provided for therein, Platform and MacDermid Performance Acquisitions Ltd. received an irrevocable undertaking (as amended on September 8, 2015) from Cevian Capital II Master Fund LP, the largest shareholder of Alent, to vote in favor of the Scheme and elect for the partial share alternative in respect of its entire beneficial ownership of 58,432,694 of Alent's shares. If no shareholders of Alent apart from Cevian Capital II Master Fund LP elect to receive new Platform shares, Cevian Capital II Master Fund LP will be issued the full amount of new Platform shares available under the partial share alternative. On July 13, 2015, in connection with the Alent Acquisition, Platform and certain subsidiary guarantors entered into an interim facility letter with Credit Suisse AG and certain of its affiliates pursuant to which they committed, subject to the terms therein, to provide Platform with a $1.88 billion interim senior unsecured term loan facility. Platform expects to replace this term loan facility with more permanent financing before or after the closing of the Alent Acquisition. The commitments under the interim facility letter, unless previously terminated, will terminate on the earlier of (i) the date on which the consummation of the Alent Acquisition is announced without the making of any advances under the term loan facility and (ii) July 13, 2016. The facility amount of $1.88 billion will be reduced by the net proceeds of any securities or other borrowings raised or issued in connection with the Alent Acquisition. The interim facility letter is subject to other terms and conditions customary for commitments and facilities of this type including certain affirmative covenants, negative covenants, conditions precedent and events of default. On August 28, 2015, the Company received notice of the early termination of the antitrust waiting period under the HSRA Act, and on September 9, 2015, the shareholders of Alent approved Platform's offer. In addition, the Company has received all necessary foreign antitrust clearances. The Scheme remains subject to the sanction of the High Court of England and Wales and certain other conditions, as set out in the Scheme sent to Alent shareholders on August 17, 2015. It is expected that, subject to the satisfaction or waiver of all relevant conditions, the Alent Acquisition will be completed in early December 2015. If the Alent Acquisition is not consummated, we may be required to pay to Alent certain costs and expenses relating to the Alent Acquisition, including a break-up fee of £27 million in the event we invoke a regulatory approvals condition on or prior to July 13, 2016 or where certain regulatory approvals conditions are not satisfied or waived on July 13, 2016, as further provided in the co-operation agreement with Alent. MacDermid Performance Acquisitions Ltd. reserves the right, subject to the prior consent of the U.K. Panel on Takeovers and Mergers and the terms of the co-operation agreement, to elect to implement the Alent Acquisition by way of a takeover offer (as such term is defined in the U.K. Companies Act). Following closing of the transaction, Platform will remain a NYSE listed company domiciled in the United States. There can be no assurances that the Alent Acquisition will be consummated. Please see the risk factors included in Platform's Annual Report, as revised and updated in Platform's quarterly report on Form 10-Q for the fiscal quarter ended June 30, 2015 for risks regarding the proposed Alent Acquisition. In connection with the Alent Acquisition, during July 2015, the Company entered into no-cost, deal contingent forward purchases of £1.06 billion ( $1.64 billion , based on the GBP/USD exchange rate of 1.5487 on July 13, 2015). The price for 50% of the forward purchases is set; however, it is dependent upon the timing of the closing of the proposed Alent Acquisition. The price for the remaining 50% allows for the Company to benefit from a weakening of the GBP relative to the USD while being protected against price movements above a maximum average of GBP/USD exchange rate of 1.6244 .

Inventories

Inventories	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Inventories	INVENTORIES The major components of inventory were as follows: (amounts in millions) September 30, December 31, 2014 Finished goods $ 321.4 $ 156.3 Work in process 16.8 — Raw materials and supplies 128.7 49.5 Total inventory, net $ 466.9 $ 205.8 In connection with the Arysta Acquisition, finished goods inventory was increased to reflect fair value. The step-up became fully amortized during the three months ended September 30, 2015. For the three and nine months ended September 30, 2015 , $1.3 million and $37.8 million , respectively, was charged to cost of sales in the Condensed Consolidated Statement of Operations. The CAS inventory step-up became fully amortized during the three months ended March 31, 2015. For the nine months ended September 30, 2015 , $20.2 million was charged to cost of sales in the Condensed Consolidated Statement of Operations in connection with the CAS Acquisition. The MacDermid inventory step-up became fully amortized during the three months ended March 31, 2014. For the nine months ended September 30, 2014 , $12.0 million was charged to cost of sales in the Condensed Consolidated Statement of Operations in connection with the MacDermid Acquisition.

Property, Plant and Equipment

Property, Plant and Equipment	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	PROPERTY, PLANT AND EQUIPMENT The major components of property, plant and equipment, including equipment under capital leases, were as follows: (amounts in millions) September 30, December 31, 2014 Land and leasehold improvements $ 44.2 $ 36.6 Buildings and improvements 83.0 47.9 Machinery, equipment, fixtures and software 180.1 109.7 Assets under capital leases 8.5 5.4 315.8 199.6 Less: accumulated depreciation (57.9 ) (25.2 ) 257.9 174.4 Construction in process 9.0 4.2 Property, plant and equipment, net $ 266.9 $ 178.6 For the three months ended September 30, 2015 and 2014 , the Company recorded depreciation expense of $11.6 million and $4.7 million , respectively. For the nine months ended September 30, 2015 and 2014 , the Company recorded depreciation expense of $33.7 million and $14.0 million , respectively. The net book value of assets acquired under capital leases was $4.3 million and $2.6 million at September 30, 2015 and December 31, 2014 , respectively. As of June 30, 2015, the Company designated Performance Application's San Marcos, CA facility, with a book value of $10.9 million , as an asset held-for-sale, in accordance with a restructuring plan to streamline the newspaper printing plate operations. The facility was sold during the third quarter of 2015 and the Company recognized a net loss on the sale of the land and building totaling $2.3 million .

Goodwill and Intangible Assets

Goodwill and Intangible Assets	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Goodwill and Intangible Assets	GOODWILL AND INTANGIBLE ASSETS The changes in the carrying amount of goodwill by segment were as follows: (amounts in millions) Performance Applications Agricultural Solutions Total December 31, 2014 $ 961.2 $ 444.1 $ 1,405.3 Addition from acquisitions — 1,697.1 1,697.1 Purchase accounting adjustments — 62.1 62.1 Foreign currency translation (58.5 ) (264.0 ) (322.5 ) September 30, 2015 $ 902.7 $ 1,939.3 $ 2,842.0 The carrying value of indefinite-lived intangible assets other than goodwill, which consist solely of tradenames, was $226 million and $69.3 million at September 30, 2015 and December 31, 2014 , respectively. During the second quarter of 2015, as a result of a decline of forecasted cash flows, the Company performed an impairment analysis of the $73.2 million of goodwill assigned to the ASF Americas reporting unit. In performing the impairment test, the Company estimated the fair value of ASF Americas pursuant to an income approach based upon discounted cash flows. For the estimate of fair value, the Company estimated annual revenue growth rates for the initial five year forecast period to range from 4.2% to 5.6% and estimated a long term growth rate in determining the terminal value of the reporting unit of 3.0% . The discount rate for the estimate of fair value was based on a Weighted Average Cost of Capital, or WACC. The WACC combines the required return on equity, based on a Modified Capital Asset Pricing Model, which considers the risk-free interest rate, market risk premium, beta, small stock risk premium and a company specific risk premium, with the cost of debt, based on BBB rated corporate bonds, adjusted using an income tax factor. The calculation resulted in a WACC rate of 10.0% . The estimated fair value of ASF Americas exceeded its carrying value by 11.8% . As a result, there was no impairment of goodwill assigned to ASF Americas. Intangible assets subject to amortization were as follows: September 30, 2015 December 31, 2014 (amounts in millions) Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Customer lists $ 946.8 $ (157.2 ) $ 789.6 $ 613.6 $ (71.6 ) $ 542.0 Developed technology 1,867.1 (322.9 ) 1,544.2 760.5 (50.8 ) 709.7 Tradenames 19.0 (2.4 ) 16.6 19.7 (1.0 ) 18.7 Non-compete agreements 1.9 (0.4 ) 1.5 1.9 (0.1 ) 1.8 Total $ 2,834.8 $ (482.9 ) $ 2,351.9 $ 1,395.7 $ (123.5 ) $ 1,272.2 Useful lives range from 8 to 30 years for customer lists, 5 to 14 years for developed technology, 5 to 20 years for tradenames and 5 years for non-compete agreements, which results in weighted average useful lives of 20 years, 12 years, 20 years and 5 years, respectively, for an aggregate weighted average useful life of approximately 15 years at September 30, 2015 . For the three months ended September 30, 2015 and 2014 , the Company recorded amortization expense on intangible assets of $50.4 million and $14.3 million , respectively. For the nine months ended September 30, 2015 , and 2014 , the Company recorded amortization expense on intangible assets of $143 million and $43.6 million , respectively. Annual amortization expense on the Company's intangible assets is estimated to total $195 million in 2015, $208 million in each of the years 2016 through 2019 , and $206 million in 2020 .

Equity Compensation Plans

Equity Compensation Plans	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Equity Compensation Plans	EQUITY COMPENSATION PLANS In June 2014, the Company’s stockholders approved the 2013 Plan. The 2013 Plan is administered by the compensation committee; provided, however, that except as otherwise expressly provided in the 2013 Plan, the Board may exercise any power or authority granted to the compensation committee under the 2013 Plan. As of September 30, 2015 , the total number of shares of common stock that may be granted as awards under the 2013 Plan is equal to 15,500,000 shares (subject to increase in accordance with the terms of the 2013 Plan). As of September 30, 2015 , a total of 440,792 shares of common stock had been issued under the 2013 Plan. Nine Months Ended September 30, 2015 Total RSUs Stock Options Equity Classified Liability Classified December 31, 2014 721,933 142,110 329,823 250,000 Granted 511,294 297,892 213,402 — Exercised/Issued (77,500 ) (2,500 ) — (75,000 ) Forfeited (282,545 ) (69,143 ) (213,402 ) — September 30, 2015 873,182 368,359 329,823 175,000 Equity Classified Share Based Payments During the nine months ended September 30, 2015 , the Board approved grants totaling of 290,250 RSUs under the 2013 Plan to certain employees of the Company, with grant-date fair values ranging from $17.08 to $27.05 per unit and vesting periods ranging from 36 months to 63.5 months. In addition, 209,290 RSUs are subject to performance conditions that must be achieved in the applicable final vesting year and 74,514 RSUs are subject to market conditions, of which 40,824 include a multiplier from zero to three times depending upon the cumulative average growth rate during a five year performance measurement period. During the nine months ended September 30, 2015 , 69,143 RSU's were forfeited, and 2,500 shares were issued. On March 17, 2015, the Board approved grants to certain directors of Platform totaling 7,642 RSUs, effective March 25, 2015, with a grant-date fair value of $27.05 . The RSUs will vest on March 17, 2016, provided that such directors continue to serve as directors of Platform through the vesting date. Each RSU represents a contingent right to receive one share of our common stock. For the three months ended September 30, 2015 and 2014 , total compensation expense associated with RSUs classified as equity totaled $0.2 million and $0.1 million , respectively. For the nine months ended September 30, 2015 and 2014 , total compensation expense associated with such RSUs totaled $0.6 million and $0.5 million , respectively. Liability Classified Share Based Payments On March 6, 2014, the Board approved a grant of 329,823 RSUs, effective on June 12, 2014 with approval of the 2013 Plan, to certain employees that cliff vest on December 31, 2020. The RSUs are subject to an EBITDA performance condition and a share price market condition. Additionally, the number of shares of common stock to be issued is limited to a maximum cash value, requiring these awards to be classified as liabilities. The combined undiscounted maximum cash value of all RSUs issued is approximately $7.1 million which is being recognized as compensation expense over the period from grant to the vesting date. During the nine months ended September 30, 2015 , the Board approved a grant of 213,402 RSUs with a grant-date fair value of $23.43 per unit that cliff vest at the end of a 24 month period, and are subject to certain performance conditions. The awards have been classified as liabilities. The undiscounted maximum cash value of all RSUs issued is approximately $5.0 million which is being recognized as compensation expense over the period from grant to the vesting date. As of September 30, 2015 all RSUs under this award were forfeited. For the three months ended September 30, 2015 and 2014 , compensation (income) expense associated with these awards totaled $(0.6) million and $0.3 million , respectively. For the nine months ended September 30, 2015 and 2014 , compensation expense associated with these awards totaled $0.8 million and $0.4 million , respectively. Stock Options On April 23, 2013, a former non-founder director was granted a five -year option to acquire 75,000 ordinary shares. This option was fully vested and, upon our Domestication, became an option to acquire shares of our common stock. On March 16, 2015, the option was exercised and 75,000 shares of our common stock were issued on March 19, 2015. Long Term Cash Bonus Plan During the three months ended March 31, 2015, the Company established the LTCB. As of September 30, 2015 , the plan provides participants the right to receive bonuses totaling $17.0 million , a decrease of $29.5 million from the second quarter of 2015 due to forfeitures. Benefits under the plan vest over periods ranging from 31 to 60 months and include EBITDA performance targets, subject to appropriate and equitable adjustments by the Board's compensation committee to reflect any subsequent acquisition, divestiture or other corporate reorganizations, as necessary. For the three and nine months ended September 30, 2015 , compensation (income) expense associated with the LTCB totaled $(0.6) million and $0.2 million , respectively. Employee Stock Purchase Plan Effective March 6, 2014, the Board adopted the ESPP, which was approved by the Company’s stockholders on June 12, 2014. The Board approved a maximum of 5,178,815 shares of common stock, which were reserved and made available for issuance under the ESPP. As of September 30, 2015 , a total of 35,676 shares had been issued under the ESPP, and approximately 700 persons were eligible to participate in the ESPP.

Pension and Post-Retirement Pla

Pension and Post-Retirement Plans	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Pension and Post-Retirement Plans	PENSION AND POST-RETIREMENT PLANS The components of net periodic pension and post-retirement benefit costs for the three and nine months ended September 30, 2015 and 2014 were as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Pension & SERP Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic (benefit) cost: Service cost $ — $ 0.2 $ — $ 0.2 $ — $ 0.6 $ — $ 0.6 Interest cost on the projected benefit obligation 1.6 0.5 1.7 0.8 4.8 1.5 5.2 2.3 Expected return on plan assets (2.4 ) (0.5 ) (2.4 ) (0.9 ) (7.2 ) (1.5 ) (7.3 ) (2.7 ) Net periodic (benefit) cost $ (0.8 ) $ 0.2 $ (0.7 ) $ 0.1 $ (2.4 ) $ 0.6 $ (2.1 ) $ 0.2 Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Post-retirement Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic cost: Interest cost on the projected benefit obligation $ 0.1 $ — $ 0.1 $ — $ 0.3 $ — $ 0.3 $ — Net periodic cost $ 0.1 $ — $ 0.1 $ — $ 0.3 $ — $ 0.3 $ — No pension service cost was recognized during the three and nine months ended September 30, 2015 and 2014 under the Domestic Pension Plan, nor will be in future periods, as benefits in the plan were frozen in connection with the MacDermid Acquisition.

Debt, Capital Leases, Financial

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Debt, Capital Leases, Financial Guarantees and Factoring Arrangements	DEBT, CAPITAL LEASES, FINANCIAL GUARANTEES AND FACTORING ARRANGEMENTS The Company’s debt and capital lease obligations consisted of the following: (amounts in millions) September 30, December 31, 2014 Borrowings under lines of credit, $ 20.0 $ — USD Notes, due 2022, 1,080.3 — EUR Notes, due 2023, 384.9 — First lien secured credit facility and term loan, due 2020, 737.4 743.0 USD Incremental Loan, due 2020, 291.3 292.7 New Tranche B Term Loan, due 2020, 121.9 121.7 New Tranche B-2 Term Loan, due 2020, 481.7 — Euro Tranche Term Loan, due 2020, 225.9 246.2 New Euro Tranche Term Loan, due 2020, 89.8 — Capital lease obligations 4.3 2.0 Total debt and capital lease obligations 3,417.5 1,405.6 Less: current portion debt and capital lease obligations (16.1 ) (13.2 ) Total long-term debt and capital lease obligations $ 3,401.4 $ 1,392.4 The Company early adopted ASU No. 2015-03, “ Simplifying the Presentation of Debt Issuance Costs” and reclassified approximately $10.3 million of debt issuance costs related to term debt from assets to contra-liabilities as of December 31, 2014, of which $1.9 million was classified as current. In August 2015, the Company entered into a series of pay fixed, receiving floating interest rate swaps with respect to a portion of its indebtedness. The swaps effectively fix the floating base rate portion of the interest payments on approximately $1.16 billion of the Company's USD denominated debt and €285 million of its Euro denominated debt at 1.96% and 1.20% , respectively, from September 2015 through June 2020. Minimum principal payments on long-term debt and capital leases were as follows: (amounts in millions) Principal Payments Year ending December 31, 2015 - remaining $ 5.3 2016 20.8 2017 20.5 2018 20.4 2019 20.4 2020 1,893.6 Thereafter 1,493.4 Total $ 3,474.4 Second Amended and Restated Credit Agreement On August 6, 2014, the Company amended and restated its senior secured credit facilities by entering into Amendment No. 2 to the First Lien Credit Facility and the Second Amended and Restated Credit Agreement, and agreeing on the implementation of certain Further Amendments to the Second Amended and Restated Credit Agreement. Upon consummation of the CAS Acquisition on November 3, 2014, the Further Amendments became effective, increasing (i) the existing U.S. Dollar revolving credit facility to $87.5 million and (ii) the existing multicurrency revolving credit facility to $87.5 million . On the date of the CAS Acquisition, the Company also borrowed (i) an aggregate principal amount of $130 million under the New Tranche B Term Loan, (ii) $60.0 million under the U.S. Dollar Revolving Credit Facility, and (iii) €55.0 million under the multicurrency Revolving Credit Facility. The amounts under (ii) and (iii) in the immediately preceding sentence were both settled by December 31, 2014. In addition, an aggregate amount of €205 million was borrowed under the Euro Tranche Term Loan by MAS Holdings and NAIP, subsidiaries of Platform. Pursuant to the Further Amendments, certain additional domestic and foreign subsidiaries of Platform and MacDermid became guarantors under the Amended and Restated Credit Agreement, and certain additional collateral was pledged to secure the Company's obligations incurred under the Euro Tranche Term Loan and the other loans incurred under the Revolving Credit Facility. With the exception of this collateral package and the interest rate, the Euro Tranche Term Loan has terms substantially similar to those of Platform’s New Tranche B Term Loan and bears interest at a rate per annum equal to an applicable margin plus an adjusted Eurocurrency Rate, calculated as set forth in the Amended and Restated Credit Agreement. The Euro Tranche Term Loan matures on June 7, 2020. On October 1, 2014, Platform and MacDermid, as borrowers, MacDermid Holdings, certain subsidiaries of MacDermid Holdings and Platform, and Barclays Bank PLC, as collateral and administrative agent and incremental lender, entered into the Incremental Amendment to the Amended and Restated Credit Agreement for an USD Incremental Loan in an aggregate principal amount of $300 million . Except as set forth in the Incremental Amendment, such USD Incremental Loan has identical terms as the existing Tranche B term loans and is otherwise subject to the provisions of the Amended and Restated Credit Agreement. The proceeds from the Incremental Amendment were used to finance the Agriphar Acquisition. On February 13, 2015, the Company entered into and closed the transactions contemplated by Amendment No. 3 to the Second Amended and Restated Credit Agreement, which, among other things, provided for (i) a New Tranche B-2 of Term Loan denominated in U.S. dollars in an aggregate principal amount of $500 million , (ii) an increase in the size of the existing Euro Tranche Term Loan by €83.0 million to €287 million , (iii) an increase in the size of the existing U.S. Dollar Revolving Credit Facility by $75.0 million to $163 million , and (iv) an increase in the size of the existing multicurrency Revolving Credit Facility by $75.0 million to $163 million . Concurrently with the closing of the Arysta Acquisition, the Company borrowed (i) a New Tranche B-2 Term Loan of $500 million (less original issue discount of 1% ), (ii) an additional New Euro Tranche Term Loan of €83.0 million (less original issue discount of 2% ), and (iii) $160 million under the U.S. Dollar Revolving Credit Facility to fund a portion of the cash consideration for the Arysta Acquisition. Certain additional domestic and foreign subsidiaries of Platform and MacDermid, including certain subsidiaries acquired in the Arysta Acquisition, have since become guarantors under the Amended and Restated Credit Agreement, with certain of the Company's subsidiaries having pledged collateral in connection therewith. The New Tranche B-2 Term Loan bears interest at a rate per annum equal to 3.75% plus an adjusted Eurocurrency rate, or 2.75% plus an adjusted base rate, calculated as set forth in the Amended and Restated Credit Agreement, and matures on June 7, 2020. Pursuant to Amendment No. 3, the previously existing New Tranche B Term Loan now bears interest at 3.50% per annum plus an adjusted Euro currency rate, or 2.50% plus an adjusted base rate, calculated as set forth in the Amended and Restated Credit Agreement. Revolving loans under the Amended and Restated Credit Agreement bear interest at a rate per annum equal to 3.00% plus an adjusted Eurocurrency rate, or 2.00% plus an adjusted base rate, each as calculated as set forth in the Amended and Restated Credit Agreement, and mature on June 7, 2018. Except as set forth in Amendment No. 3 and above, the New Tranche B-2 Term Loan has identical terms as the existing New Tranche B Term Loan and is otherwise subject to the provisions of the Amended and Restated Credit Agreement. Covenants and Events of Default The Amended and Restated Credit Agreement contains customary covenants including limitations on additional indebtedness, dividends and other distributions, entry into new lines of business, use of loan proceeds, capital expenditures, restricted payments, restrictions on liens, transactions with affiliates, amendments to organizational documents, accounting changes, sale and leaseback transactions and dispositions. Amendment No. 3, among other things, provides additional flexibility with respect to certain negative covenants, including by increasing certain dollar baskets as compared to the previous amendments. The Revolving Credit Facility also imposes a financial covenant, if borrowings under the Revolving Credit Facility and letter of credit obligations exceed 25% of the revolving credit commitments as of the last day of any fiscal quarter, which limits Platform to a 6.5 to 1.0 ratio of (x) consolidated indebtedness secured by a first lien minus unrestricted cash and cash equivalents of the borrowers and guarantors under the Amended and Restated Credit Agreement to (y) consolidated EBITDA for the four most recent fiscal quarters, subject to a right to cure. As of September 30, 2015 , the Company was in compliance with the debt covenants contained in its Credit Facilities. The Amended and Restated Credit Agreement also contains customary events of default that include, among others, non-payment of principal, interest or fees, violation of certain covenants, inaccuracy of representations and warranties, failure to make payment on certain other material indebtedness, bankruptcy and insolvency events, material judgments and change of control provisions. Upon the occurrence of an event of default, payment of any outstanding loans under the Amended and Restated Credit Agreement may be accelerated. Borrowings under the Amended and Restated Credit Agreement are also subject to mandatory prepayment from the proceeds of certain dispositions of assets and from certain insurance and condemnation proceeds, excess cash flow and debt incurrences, in each case, subject to customary carve-outs and exceptions. Guarantees The obligations of Platform and MacDermid, as borrowers, under the Amended and Restated Credit Agreement are guaranteed by current and future direct and indirect domestic subsidiaries. Certain of Platform's foreign subsidiaries also guarantee the obligations of MAS Holdings and NAIP with respect to the Euro Tranche Term Loan and the New Euro Tranche Term Loan. Pursuant to the Security Agreement, the Company's obligations under the Amended and Restated Credit Agreement are secured by a security interest in substantially all of the personal property, whether owned on the date the Security Agreement, or entered into or acquired in the future, of Platform and MacDermid, as borrowers, and the guarantors listed in the Security Agreement, including the pledge by Platform, MacDermid and guarantors generally of 100% of the voting common stock and other equity interests in all of their respective domestic subsidiaries and 65% of the voting common stock and other equity interests in all of their respective directly owned non-domestic subsidiaries (in each case, whether existing on the date the Security Agreement or entered into or acquired thereafter), subject to certain exceptions contained in the Amended and Restated Credit Agreement and the Security Agreement. January Notes Offering In connection with the Arysta Acquisition, on February 2, 2015, Platform completed the January Notes Offering of $1.10 billion aggregate principal amount of 6.50% USD Notes due 2022, plus original issue premium of $1.0 million , and €350 million aggregate principal amount of 6.00% EUR Notes due 2023. The Notes are governed by an indenture, dated February 2, 2015, as amended by a first supplemental indenture dated February 13, 2015 and a second supplemental indenture dated May 20, 2015. The 6.50% USD Notes due 2022 and the 6.00% EUR Notes due 2023 mature on February 1, 2022 and February 1, 2023, respectively, unless earlier redeemed. The 6.50% USD Notes due 2022 and the 6.00% EUR Notes due 2023 bear interest at a rate of 6.50% and 6.00% per year, respectively, until maturity. Interest is payable in cash, semi-annually in arrears, on February 1 and August 1 of each year, beginning on August 1, 2015. Platform will make each interest payment to the holders of record to be determined on the immediately preceding January 15 and July 15. The notes are (i) Platform’s senior unsecured obligations, ranking equally in right of payment with all of Platform’s existing and future senior unsecured debt and ranking senior in right of payment to all of Platform’s existing and future unsecured subordinated debt; (ii) effectively subordinated to Platform’s secured indebtedness, including the debt outstanding under the Amended and Restated Credit Agreement, to the extent of the value of the assets securing such debt, and are structurally subordinated to indebtedness and other liabilities, including trade payables, of Platform’s non-guarantor subsidiaries; and (iii) jointly and severally, fully and unconditionally guaranteed on a senior unsecured basis generally by current and future direct and indirect domestic subsidiaries that guarantee the Amended and Restated Credit Agreement. Lines of Credit and Other Debt Facilities The Company carries various lines of credit, short-term debt facilities and overdraft facilities worldwide which are used to fund short-term cash needs. As of September 30, 2015 , borrowings under such facilities totaled $20.0 million . At December 31, 2014 , there were no borrowings under such facilities. The Company also had letters of credit outstanding of $26.6 million and $1.0 million at September 30, 2015 and December 31, 2014 , respectively, of which $1.9 million and $1.0 million reduce the borrowings available under the various credit facilities at September 30, 2015 and December 31, 2014 , respectively. At September 30, 2015 and December 31, 2014 , the availability under these facilities was approximately $398 million and $195 million , respectively, net of outstanding letters of credit. As of September 30, 2015 , interest rates on such facilities ranged from 0.45% to 11.35% . Financial Guarantees and Factoring Arrangements The Company periodically enters into certain arrangements with vendors and customers under which it provides guarantees to financial institutions for loans entered into between its vendors and customers and the financial institutions, the proceeds of which are used to settle outstanding accounts receivables. The terms of the guarantees are equivalent to the terms of the customer loans. Liabilities for the guarantees are recorded at amounts that approximate fair value, based on the Company’s historical collection experience with vendors and customers that participate in the program and a current assessment of credit exposure. Such liabilities are included in "Financial guarantees and factoring" in the Company's Condensed Consolidated Balance Sheet, and totaled $40.7 million and zero as of September 30, 2015 and December 31, 2014 , respectively. Program income and expenses are recorded in "Interest expense, net" in the Condensed Consolidated Statement of Operations and totaled $0.5 million for the three months ended September 30, 2015 and 2014 . For the nine months ended September 30, 2015 and 2014 , the Company recorded program expenses of $1.5 million and zero , respectively. The Company also utilizes accounts receivable factoring arrangements as a part of its working capital management strategies. Total current capacity under such programs is approximately $250 million as of September 30, 2015 . Under these arrangements, factored accounts receivable may be transferred with or without recourse. Factoring transactions qualifying for sales treatment, where the derecognition criteria have been met, totaled $121.4 million and zero as of September 30, 2015 and December 31, 2014 , respectively. Account receivable balances related to arrangements not having met the derecognition criteria, whereas the risks and rewards of ownership have not been transferred, remain recorded in "Account receivable" and the related liabilities are included in "Financial guarantees and factoring" in the Company's Condensed Consolidated Balance Sheet, and totaled $18.3 million and zero as of September 30, 2015 and December 31, 2014 , respectively. Factoring fees are recorded in "Interest expense, net" in the Condensed Consolidated Statement of Operations and totaled $0.1 million and zero for the three months ended September 30, 2015 and 2014 , respectively. For the nine months ended September 30, 2015 and 2014 , the Company recorded factoring fees of $0.1 million and zero , respectively.

Derivative Instruments

Derivative Instruments	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivative Instruments	DERIVATIVE INSTRUMENTS In the normal course of business, the Company is exposed to risks relating to changes in foreign currency exchange rates, interest rates and commodity prices. Derivative financial instruments, such as foreign currency exchange rate instruments and interest rate swaps, are used to manage changes in market conditions related to foreign currency exchange rate and interest rate volatility. All derivatives are recognized on the Condensed Consolidated Balance Sheets at fair value at the end of each period. The counterparties to the Company’s derivative agreements are major international financial institutions. The Company continually monitors its positions and the credit ratings of its counterparties and does not anticipate nonperformance by the counterparties. Foreign Currency The Company conducts a significant portion of its business in currencies other than the U.S. dollar, the currency in which the unaudited interim Condensed Consolidated Financial Statements are reported, and as a result, the Company’s operating results are affected by foreign currency exchange rate volatility relative to the U.S. dollar. As of September 30, 2015 , the aggregate U.S. dollar notional amount of foreign currency forward contracts, none of which were designated as hedges, totaled $910 million , all with settlement dates within one year. The majority of forward contracts are in British pounds ( £533 million ) and US dollars ( $99.8 million ), with lesser amounts in Chinese yuans, Euros, New Zealand dollars and Australian dollars. The market value of forward contracts are determined using pricing models based upon observable market inputs including both forward and spot prices for the underlying currencies. The net fair value of the foreign currency forward contracts is recorded as an unrealized gain (loss) under "Other (expense) income, net" in the accompanying Condensed Consolidated Statement of Operations. In connection with the proposed Alent Acquisition, during July 2015, the Company entered into no-cost, deal contingent forward purchases of £1.06 billion ( $1.64 billion , based on the GBP/USD exchange rate of 1.5487 on July 13, 2015). The price for 50% of the forward purchases is set; however, it is dependent upon the timing of the closing of the proposed Alent Acquisition. The price for the remaining 50% allows for the Company to benefit from a weakening of the GBP relative to the USD while being protected against price movements above a maximum average of GBP/USD exchange rate of 1.6244 . Interest Rates In August 2015, the Company entered into a series of pay fixed, receiving floating interest rate swaps with respect to a portion of its indebtedness. The swaps effectively fix the floating base rate portion of the interest payments on approximately $1.16 billion of the Company's USD denominated debt and €285 million of its Euro denominated debt at 1.96% and 1.20% , respectively, from September 2015 through June 2020. Changes in the fair value of a derivative that is designated as, and meets all the required criteria for, a cash flow hedge are recorded in accumulated other comprehensive income (loss) and reclassified into earnings as the underlying hedged item affects earnings. Amounts reclassified into earnings related to the interest rate swaps are included in interest expense. The following table summarizes the fair value of derivative instruments reported in the Condensed Consolidated Balance Sheets: (amounts in millions) September 30, December 31, 2014 Derivatives designated as hedging instruments Liabilities Balance Sheet Location Interest Rate Swaps Other current liabilities $ 18.1 $ — Derivatives not designated as hedging instruments: Assets Balance Sheet Location Foreign exchange contracts Prepaid expenses & other current assets 0.5 — Other Assets 0.7 — Liabilities Balance Sheet Location Foreign exchange contracts Other current liabilities 48.6 0.1 Total derivative contracts - Asset (Liability) $ (65.5 ) $ (0.1 ) For the three and nine months ended September 30, 2015 , there were $18.1 million unrealized losses recorded in Other Comprehensive Income related to foreign currency hedges. For the three months ended September 30, 2014 , there were no unrealized gains (losses) recorded in "Other Comprehensive Income" related to foreign currency hedges. For the nine months ended September 30, 2014 , unrealized losses totaled $0.2 million . For the three and nine months ended September 30, 2015 , the Company recorded $47.3 million and $49.9 million , respectively, of net unrealized losses in "Loss on derivative contracts" related to hedged foreign exchange contracts. For the three and nine months ended September 30, 2014 , the Company recorded $2.6 million and $2.2 million respectively, of net unrealized losses in "Loss on derivative contracts" related to hedged foreign exchange contracts.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value Measurements	FAIR VALUE MEASUREMENTS The Company determines fair value measurements used in its consolidated financial statements based upon the exit price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants exclusive of any transaction costs, as determined by either the principal market or the most advantageous market. The principal market is the market with the greatest level of activity and volume for the asset or liability. Absent a principal market to measure fair value, the Company has used the most advantageous market, which is the market in which the Company would receive the highest selling price for the asset or pay the lowest price to settle the liability, after considering transaction costs. However, when using the most advantageous market, transaction costs are only considered to determine which market is the most advantageous and these costs are then excluded when applying a fair value measurement. Inputs used in the valuation techniques to derive fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below with Level 1 having the highest priority and Level 3 having the lowest. The three levels of the fair value hierarchy are as follows: • Level 1 – quoted prices (unadjusted) in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date. • Level 2 – quoted prices for similar instruments in active markets; quoted prices for identical or similar instruments in non-active markets; and model derived valuations whose inputs are observable or whose significant valuation drivers are observable. • Level 3 – significant inputs to the valuation model are unobservable and/or reflect the Company’s market assumptions. Recurring Fair Value Measurements The following tables present the Company’s financial instruments, assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurement Using (amounts in millions) September 30, Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 36.2 $ 36.2 $ — $ — Available for sale equity securities 6.9 6.2 0.7 — Derivatives 1.2 — 1.2 — Total $ 44.3 $ 42.4 $ 1.9 $ — Liability Category Long term contingent consideration $ 70.2 $ — $ — $ 70.2 Derivatives 66.7 — 18.6 48.1 Total $ 136.9 $ — $ 18.6 $ 118.3 Fair Value Measurement Using (amounts in millions) December 31, 2014 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 15.4 $ 15.4 $ — $ — Available for sale equity securities 2.3 1.5 0.8 — Total $ 17.7 $ 16.9 $ 0.8 $ — Liability Category Long term contingent consideration $ 63.9 $ — $ — $ 63.9 Derivatives 0.1 — 0.1 — Total $ 64.0 $ — $ 0.1 $ 63.9 Money market accounts are included in "Cash and cash equivalents" in the Condensed Consolidated Balance Sheets. Available for sale equity securities are included in "Other assets" in the Condensed Consolidated Balance Sheets. The following methods and assumptions were used to estimate the fair value of each class of the Company’s financial instruments, assets and liabilities: Money market accounts - The Company invests in various money market funds which are managed by financial institutions. These money market funds are not publicly traded, but historically have been highly liquid. The fair value of the money market accounts is determined by the banks based upon the funds’ net asset values, or NAV. All of the money market accounts currently permit daily investments and redemptions at $1.00 NAV. Available for sale equity securities - Equity securities classified as available for sale are measured using quoted market prices at the reporting date multiplied by the quantity held. Level 2 equity securities are measured using quoted prices for similar instruments in active markets. Derivatives - The fair values of our derivative assets and liabilities include foreign currency and interest rate derivatives. The values were determined using pricing models based upon observable market inputs, and for the deal contingent forward purchase derivative, the value was determined using pricing models based on third party pricing valuations of broker/ dealer quotations not based upon observable market inputs. Long term contingent consideration - The long term contingent consideration represents a potential liability of up to $100 million tied to achievement of EBITDA and common stock trading price performance metric over a seven -year period ending December 2020 in connection with the MacDermid Acquisition. The common stock performance metric has been satisfied. The fair value of the EBITDA performance metric is derived using the income approach with unobservable inputs, based on future forecasts and present value assumptions which include a discount rate of approximately 1.5% and expected future value of payments of $60.0 million calculated using a probability weighted EBITDA assessment with higher probability associated with the Company achieving the maximum EBITDA targets. For the three and nine month ended September 30, 2015 , the fair value of the long term contingent consideration increased by $2.7 million and $6.3 million , respectively. For the three and nine month ended September 30, 2014 , the fair value of the long term contingent consideration increased by $2.3 million and $26.1 million , respectively. Changes in the fair value of the long term contingent consideration is recorded in "Selling, technical, general and administrative expenses" in the Condensed Consolidated Statement of Operations. An increase or decrease in the discount rate of 1% changes the fair value measure of the share price metric by $2.0 million . As of September 30, 2015 and 2014 , there were no significant transfers between the fair value hierarchy levels. Nonrecurring Fair Value Measurements The following table presents the carrying value and estimated fair value of the Company’s long term debt and capital lease obligations: (amounts in millions) September 30, 2015 December 31, 2014 Long term debt - including current portion Carrying Value Fair Value Carrying Value Fair Value USD Notes, due 2022, interest at 6.50% $ 1,080.3 $ 935.0 $ — $ — EUR Notes, due 2023, interest at 6.00% 384.9 334.5 — — First Lien Credit Facility 737.4 712.0 743.0 721.4 USD Incremental Loan 291.3 286.6 292.7 286.0 New Tranche B Term Loan 121.9 124.2 121.7 125.2 New Tranche B-2 Term Loan 481.7 478.9 — — Euro Tranche Term Loan 225.9 218.9 246.2 245.8 New Euro Tranche Term Loan 89.8 88.9 — — Capital lease obligations 4.3 4.2 2.0 2.6 Total $ 3,417.5 $ 3,183.2 $ 1,405.6 $ 1,381.0 The following methods and assumptions were used to estimate the fair value of the Company’s long term debt: Long-term Debt Instruments - These financial instruments are measured using quoted market prices at the reporting date multiplied by the gross carrying amount of the related debt. Such instruments are valued using Level 2 inputs.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Sep. 30, 2015
Stockholders' Equity Note [Abstract]
Stockholders' Equity	STOCKHOLDERS’ EQUITY Underwritten Public Offering On June 23, 2015, we entered into an underwriting agreement with Credit Suisse Securities (USA) LLC and Barclays Capital Inc., as representatives of several underwriters relating to the June 2015 Equity Offering of 18,226,414 shares of our common stock at a public offering price of $26.50 per share. This number of shares includes 2,377,358 shares sold to the underwriters upon exercise in full of their option to purchase additional shares. The June 2015 Equity Offering was registered with the SEC pursuant to a Registration Statement on Form S-3, as amended (File Nos. 333-205010 and 333-205181), initially filed by Platform on June 17, 2015. The June 2015 Equity Offering closed on June 29, 2015 and resulted in gross proceeds to Platform of approximately $483 million , before underwriting discounts, commissions and offering expenses of $14.8 million . Preferred Stock Pursuant to the Company's Certificate of Incorporation, as amended, 5,000,000 shares of preferred stock are authorized. The Board has designated 2,000,000 shares as "Series A Preferred Stock." As of September 30, 2015 and December 31, 2014 , a total of 2,000,000 shares were issued and outstanding. The Board has also designated 600,000 shares as "Series B Convertible Preferred Stock," which are redeemable and are presented in the mezzanine section of the Company's Condensed Consolidated Balance Sheet. As of September 30, 2015 and December 31, 2014 , a total of 600,000 and zero shares, respectively, were issued and outstanding. Shares of preferred stock have no voting rights, except in respect of any amendment to the Company's Certificate of Incorporation, as amended, that would alter or change their rights or privileges. Series A Preferred Stock The Founder Entities are the current holders of our outstanding 2,000,000 shares of Series A Preferred Stock and are entitled to receive dividends on such Series A Preferred Stock in the form of shares of common stock. On December 31, 2014 , the Company approved a stock dividend of 10,050,290 shares of our common stock with respect to our outstanding Series A Preferred Stock. The dividend price was $22.85 , and the shares were issued on January 2, 2015 based on the volume weighted average price of $23.16 on December 31, 2014 . Each share of Series A Preferred Stock is convertible into one share of common stock at the option of the holders until December 31, 2020. Shares of Series A Preferred Stock will be automatically converted into shares of common stock on a one for one basis (i) in the event of a change of control of the Company following an acquisition or (ii) upon the last day of the seventh full financial year following the MacDermid Acquisition, being December 31, 2020 (which may be extended by the Board for three additional years). Series B Convertible Preferred Stock In connection with the Arysta Acquisition, the Company issued to the Seller 600,000 shares of Series B Convertible Preferred Stock, which have a $1,000 per share liquidation preference. The fair value of these shares, $646 million , was recognized as "Redeemable preferred stock – Series B" in the Condensed Consolidated Balance Sheet. At any time, the Seller may convert these shares into common stock of Platform at a conversion price of $27.14 . Additionally, any shares that have not been converted will be redeemed for the $1,000 per share liquidation preference in the event of (i) certain mergers or consolidations, (ii) the sale of substantially all the Company’s assets or subsidiaries or (iii) the liquidation of the Company. Further, any shares that are not converted or redeemed will mandatorily convert to shares of common stock of Platform on October 20, 2016 at the $27.14 conversion price. Upon such mandatory conversion, the Company will pay the Seller in cash any deficit between (i) the 10 -day volume weighted price of Platform’s common stock prior to such mandatory conversion and (ii) $27.14 per share. Such make whole payment may be reduced by the outcome of the arbitration matter described in Note 15 of the unaudited interim Condensed Consolidated Financial Statements. If such make whole payment is less than the amount resolved in connection with this arbitration matter, the deficit will be due from the Seller. Based on Platform's common stock price of $12.65 as of September 30, 2015 , the make whole payment would total approximately $320 million , assuming no reduction for the arbitration matter noted above. On October 27, 2015, certain terms of the Series B Convertible Preferred Stock were amended. See Note 21, Subsequent Events. In connection with the issuance of the Series B Convertible Preferred Stock, the Company entered into a registration rights agreement with the Seller dated February 17, 2015, pursuant to which it agreed to (i) file a registration statement with the SEC covering the resale of a maximum of 22,107,590 shares of common stock issuable upon conversion of the Series B Convertible Preferred Stock, as soon as reasonably practicable following the issuance of the Series B Convertible Preferred Stock, and (ii) use its commercially reasonable efforts to cause the SEC to declare such registration statement effective by not later than six months following the date of the registration rights agreement. On February 25, 2015, the Company filed the Seller Resale Registration Statement to register the resale of a maximum of 22,107,590 shares of common stock. Such resale registration statement was amended on March 20, 2015 and April 29, 2015, and declared effective by the SEC on May 6, 2015. Option Exercise On April 23, 2013, a former non-founder director was granted a five -year option to acquire 75,000 ordinary shares. This option was fully vested and, upon our Domestication, became an option to acquire shares of our common stock. On March 16, 2015, the option was exercised and 75,000 shares of our common stock were issued on March 19, 2015. Non-Controlling Interest In connection with the MacDermid Acquisition, approximately $97.5 million was raised in new equity consisting of shares of PDH Common Stock. Since October 31, 2014, all shares of PDH common stock are convertible, at the option of the holder, into a like number of shares of the Company's common stock, the sale of which is subject to a contractual lock-up of 25% per year over a four-year period, which started on October 31, 2013. The PDH Common Stock is classified as a non-controlling interest on the Condensed Consolidated Balance Sheets at September 30, 2015 and December 31, 2014 and will continue to be until such time as it is fully converted in shares of the Company's common stock. The total number of shares of common stock originally issuable upon the exchange of PDH Common Stock pursuant to the RHSA was approximately 8.8 million , against which 567,920 shares have been issued as of September 30, 2015 . For the three months ended September 30, 2015 and 2014 , approximately $(1.1) million and $2.1 million , respectively, of net (loss) income has been allocated to the Retaining Holders, as included in the Condensed Consolidated Statements of Operations, representing non-controlling interest of 6.35% and 6.76% at September 30, 2015 and 2014 , respectively. For the nine months ended September 30, 2015 and 2014 , approximately $0.1 million and $5.2 million , respectively, of net income has been allocated to the Retaining Holders, as included in the Condensed Consolidated Statements of Operations. As a result of the Arysta Acquisition, approximately $31.0 million of non-controlling interest was recorded in purchase accounting as a result of the consolidation of less-than-wholly-owned subsidiaries.

Accumulated Other Comprehensive

Accumulated Other Comprehensive (Loss) Income	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Accumulated Other Comprehensive (Loss) Income	ACCUMULATED OTHER COMPREHENSIVE (LOSS) INCOME A summary of the changes in each component of accumulated other comprehensive (loss) income, net of tax for the three and nine months ended September 30, 2015 and 2014 were as follows: Three Months Ended September 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Loss Balance at June 30, 2015 $ (386.0 ) $ (15.4 ) $ 0.3 $ — $ 13.5 $ (387.6 ) Other comprehensive (loss) income before reclassifications, net (350.2 ) — 1.0 (11.8 ) 7.2 (353.8 ) Balance at September 30, 2015 $ (736.2 ) $ (15.4 ) $ 1.3 $ (11.8 ) $ 20.7 $ (741.4 ) Nine Months Ended September 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2014 $ (122.2 ) $ (14.9 ) $ 0.1 $ — $ 6.4 $ (130.6 ) Other comprehensive (loss) income before reclassifications, net (614.0 ) — 1.2 (11.8 ) 14.3 (610.3 ) Tax benefit reclassified — (0.5 ) — — — (0.5 ) Balance at September 30, 2015 $ (736.2 ) $ (15.4 ) $ 1.3 $ (11.8 ) $ 20.7 $ (741.4 ) Three Months Ended September 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Income (Loss) Balance at June 30, 2014 $ 22.4 $ 2.0 $ — $ — $ (1.3 ) $ 23.1 Other comprehensive (loss) income before reclassifications, net (60.3 ) — (0.1 ) — 3.8 (56.6 ) Balance at September 30, 2014 $ (37.9 ) $ 2.0 $ (0.1 ) $ — $ 2.5 $ (33.5 ) Nine Months Ended September 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2013 $ (0.6 ) $ 1.8 $ — $ 0.1 $ — $ 1.3 Other comprehensive (loss) income before reclassifications, net (37.3 ) 0.2 — — 2.5 (34.6 ) Reclassifications, pretax — — (0.1 ) (0.2 ) — (0.3 ) Tax expense reclassified — — — 0.1 — 0.1 Balance at September 30, 2014 $ (37.9 ) $ 2.0 $ (0.1 ) $ — $ 2.5 $ (33.5 )

Earnings Per Share

Earnings Per Share	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Earnings Per Share	EARNINGS PER SHARE A computation of the weighted average shares outstanding for the three and nine months ended September 30, 2015 and 2014 follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions, except per share amounts) 2015 2014 2015 2014 Net loss attributable to common stockholders $ (122.3 ) $ 11.9 $ (161.1 ) $ 4.1 Basic weighted average common stock outstanding 210.9 137.3 198.6 124.5 Number of shares contingently issuable for founder preferred share dividend rights — 11.7 — 11.7 Number of shares issuable upon conversion of founder preferred shares — 2.0 — 2.0 Number of shares contingently issuable for the contingent consideration — 1.6 — 0.4 Number of warrants — — — 1.5 Number of shares issuable upon conversion of the 401k exchange rights — — — 0.3 Number of stock options — 0.1 — 0.1 Convertible and performance-based stock — 15.4 — 16.0 Dilutive weighted average common stock outstanding 210.9 152.7 198.6 140.5 Earnings per share attributable to common stockholders: Basic $ (0.58 ) $ 0.09 $ (0.81 ) $ 0.03 Diluted $ (0.58 ) $ 0.08 $ (0.81 ) $ 0.03 For the three and nine month ended September 30, 2015 , no share adjustments are included in the dilutive weighted average shares outstanding computation as their effect would have been anti-dilutive. For more information about such dilutive shares outstanding, refer to the table below. For the three and nine months ended September 30, 2015 and 2014 , the following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because performance targets were not yet achieved for awards contingent upon performance. Three Months Ended September 30, Nine Months Ended September 30, (amounts in thousands) 2015 2014 2015 2014 Number of shares contingently issuable to Founder Entities as stock dividend to Series A Preferred Stock — — 1,652 — Number of shares issuable upon conversion of PDH Common Stock 8,207 8,775 8,207 8,775 Number of shares issuable upon conversion of Series A Preferred Stock 2,000 — 2,000 — Number of shares issuable upon conversion of Series B Convertible Preferred Stock 22,108 — 18,544 — Number of shares contingently issuable for the contingent consideration 2,496 — 1,719 1,161 Number of stock options 55 — 70 — Number of restricted stock shares and units 60 19 94 8 Number of shares issuable under the employee stock purchase plan 2 — 1 — 34,928 8,794 32,287 9,944

Operating Lease Commitments

Operating Lease Commitments	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Operating Lease Commitments	OPERATING LEASE COMMITMENTS The Company leases certain land, office space, warehouse space and equipment under agreements which are classified as operating leases for financial statement purposes. Certain of these leases provide for payment of real estate taxes, common area maintenance, insurance and certain other expenses. Lease terms may have escalating rent provisions and rent holidays which are recognized on a straight-line basis over the term of the lease. The leases expire at various dates through 2047. Total rental expense for operating leases was as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Rent Expense $ 6.0 $ 2.5 $ 16.4 $ 7.5 Minimum non-cancelable operating lease commitments were as follows: (amounts in millions) Operating Lease Payment Year ending December 31, 2015, remaining $ 4.5 2016 15.0 2017 10.3 2018 6.7 2019 5.4 2020 5.5 Thereafter 18.7 $ 66.1 The fixed operating lease commitments detailed above assume that the Company continues the leases through their initial lease terms.

Contingencies, Environmental an

Contingencies, Environmental and Legal Matters	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Contingencies, Environmental and Legal Matters	CONTINGENCIES, ENVIRONMENTAL AND LEGAL MATTERS Asset Retirement Obligations The Company has recognized asset retirement obligations, or AROs, for properties where it can make a reasonable estimate of the future expenditures necessary to satisfy the related obligations. The Company considers identified legally enforceable obligations, estimated settlement dates and appropriate discount and inflation rates in calculating the fair value of its AROs. As of September 30, 2015 and December 31, 2014 , the Company's ARO reserves, included in other current and long term liabilities in the Condensed Consolidated Balance Sheets, totaled $17.8 million and $18.5 million , respectively, for sites in Europe, Latin America and North America. Changes in the Company’s AROs were as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 AROs, beginning of period $ 17.7 $ 5.4 $ 18.5 $ 4.8 Acquisitions — 0.1 0.4 0.4 Accretion expense 0.2 0.2 0.7 0.5 Remeasurements 0.5 — (0.2 ) — Payments (0.4 ) — (0.4 ) — Foreign currency adjustments (0.2 ) (0.2 ) (1.2 ) (0.2 ) AROs, end of period $ 17.8 $ 5.5 $ 17.8 $ 5.5 Environmental The Company formulates and distributes specialty chemical products, and is exposed to claims with respect to environmental cleanup or other matters, including those in connection with the disposal of hazardous materials. The Company is subject to extensive domestic and foreign laws and regulations relating to environmental protection and worker health and safety, including those governing discharges of pollutants into the air and water, the management and disposal of hazardous substances and wastes, and the cleanup of contaminated properties. The Company has incurred, and will continue to incur, costs and capital expenditures in complying with these laws and regulations. Additional costs could be incurred, including cleanup costs, fines, sanctions, and third-party claims, as a result of violations of or liabilities under environmental laws. Remediation activities vary substantially in duration and cost from site to site. These activities, and their associated costs, depend on the mix of unique site characteristics, evolving remediation technologies, diverse regulatory agencies and enforcement policies, as well as the presence or absence of potentially responsible parties. The Company has received notices of violation with respect to instances of non-compliance with environmental laws. A number of facilities and former facilities of the Company have been environmentally impacted from historic operations and some facilities are in the process of being investigated and remediated. As of September 30, 2015 and December 31, 2014 , approximately $1.7 million and $4.5 million , respectively, was reserved for various environmental matters. Ultimate costs may vary from current estimates. The discovery of additional contaminants at these facilities or other sites or the imposition of additional cleanup obligations or third-party claims relating thereto could result in additional costs. Management believes that any possible losses related to environmental remediation in addition to the amounts recorded as of September 30, 2015 and December 31, 2014 would not be material to the Company’s consolidated financial position, results of operations or cash flows. Legal Proceedings From time to time, the Company is involved in various legal proceedings in the normal course of its business. We believe that the resolution of these claims, to the extent not covered by insurance, will not individually or in the aggregate, have a material adverse effect on the Company’s consolidated financial position, results of operations or cash flows. As of September 30, 2015 and December 31, 2014 , the Company has reserved approximately $6.6 million and $4.4 million , respectively, for its outstanding legal proceedings. The following is a description of certain litigation matters. Product liability and/or personal injury claims for, or relating to, products we sell under our Agricultural Solutions segment are complex in nature and have outcomes that are difficult to predict. Since these products are used in the food chain on a global basis, any such product liability or personal injury claim could lead to litigation in multiple jurisdictions. During 2014, Agricola Colonet, SA de CV claimed that certain Arysta products purchased from a retail distributor in Mexico were contaminated, requiring treated crops to be destroyed. Agricola Colonet, SA de CV is seeking compensation of approximately MXN 181 million ( $10.7 million , based on the MXN/ USD exchange rate of 0.0591 on September 30, 2015 ). The Company believes that it has adequate defenses and intends to vigorously defend against this claim, and therefore has not established a reserve related to this claim. Under its risk management policies, the Company maintains certain insurance policies under which such claims may be covered. In March 2013, a claim was filed against Arysta LifeScience Corporation, a subsidiary of the Company, relating to a purchasing optimization agreement entered into in 2011 between Arysta LifeScience Corporation and a consulting firm. The agreement provided for an incentive fee to be paid to the plaintiff based upon savings to Arysta resulting from the plaintiff's work. In addition to fees already received, the plaintiff claims damages, which the Company considers to be non-material. The Company believes this claim is without merit and that the fees already paid under the agreement exceed or equal the fees owed to the plaintiff. An arbitration hearing was conducted in May 2014, and in May 2015 the tribunal published a partial award, ruling on various issues of principle, but declining to calculate an award amount, rather asking the parties to attempt to agree upon a calculation reflecting the decisions of the tribunal set out in the award. The plaintiff subsequently filed for an application for clarification of the partial award, to which we responded by filing our own calculation of the award. The tribunal issued its clarification of the partial award, and we are awaiting submission by the plaintiff of its calculation of the award, after which further decisions from the tribunal are expected. The $600 million of Series B Convertible Preferred Stock issued in connection with the Arysta Acquisition may be converted into a maximum of 22,107,590 shares of Platform common stock. To the extent that the aggregate value of such shares is less than $600 million (based on a 10 -day volume weighted average price), then, such shortfall would be payable in cash by Platform. Such shortfall would however be reduced by a portion, or all, of the amount for which the arbitration matter described in the preceding paragraph may be resolved, either by order of the arbitrators or by settlement, pursuant to a formula negotiated by and between the Company and the Seller. In June 2009, a lawsuit was filed by a private individual against Arysta LifeScience do Brasil Industria Química e Agropecuária Ltda, or Arysta Brazil, and 25 other defendants, and in November 2011, a claim was filed against Arysta Brazil and five other defendants by the city of Ulianopolis, in each case in connection with materials sent by Arysta Brazil and others to an incineration site owned and operated by an unaffiliated third party in the state of Pará, Brazil. Arysta Brazil was summoned and has filed its answer in connection with both cases. Proceedings have been suspended until October 15, 2015 in order to allow the Pará State Attorney to conduct civil inquiries to determine the extent of contamination and the appropriate remediation, and to identify potentially responsible parties. Damages sought in the private lawsuit include a penalty of BRL 50.0 million ( $12.6 million , based on the BRL/USD exchange rate of 0.2527 on September 30, 2015 ), plus interest and the cost of remediation. The cost of remediation in the case brought by the city of Ulianopolis was previously estimated by the city to be BRL 70.9 million ( $17.9 million , based on the BRL/USD exchange rate of 0.2527 on September 30, 2015 ). In addition, 13 former employees of the incineration facility have brought actions naming 80 defendants, including Arysta Brazil, seeking compensation in an aggregate amount of BRL 173.3 million ( $43.8 million , based on the BRL/USD exchange rate of 0.2527 on September 30, 2015 ) for health problems allegedly contracted as a result of their employment at the incineration site. In April 2014, Arysta LifeScience North America, LLC, or ALSNA, was served by Natividad and Francisco Sanchez, as plaintiffs, with a complaint naming over 30 defendants, including several chemical companies and crop protection companies. The complaint alleges that one of the plaintiffs was exposed to various products during the course of employment with various employers between 1989 and 2012, and that those products caused the plaintiff to develop medical conditions, including acute myelogenous leukemia. The plaintiffs are seeking monetary damages in the amount of $13.2 million . ALSNA filed its answer in May 2014 and later negotiated a settlement with the plaintiffs for a total settlement amount, which we consider to be non-material, and for which a settlement agreement is expected to be executed shortly. From time to time, in the ordinary course of our business, we contest tax assessments received by our subsidiaries in various jurisdictions. Our contested tax assessments have been most prevalent in Brazil, where the tax regime is complex, and the administrative and judicial procedures for resolving disputed tax assessments are expensive and time-consuming. In addition, short of simply paying the entire amount demanded, including penalties, interest, and attorney’s fees, it is not possible to settle disputed tax assessments other than by submission for inclusion in formal tax amnesty programs announced by the Brazilian federal or state governments from time to time at irregular intervals. The terms of such amnesty programs vary, but generally offer the possibility of reduced interest and penalties. In the past, Arysta has submitted selected contested tax matters for inclusion in such amnesty programs in Brazil, when it appeared prudent to management to do so, and we are currently contesting several tax assessments at various stages of the applicable administrative and judicial processes, with a combined amount at issue, including interest and penalties, of approximately BRL 41.8 million ( $10.6 million , based on the BRL/USD exchange rate of 0.2527 on September 30, 2015 ). Because tax matters in Brazil historically take many years to resolve, it is very difficult to estimate when these matters will be finally resolved. Based on management's judgments, the Company does not expect it will incur a material loss in excess of accrued liabilities. In February 2015, MacDermid, as plaintiff, settled a litigation with Cookson Group plc, Enthone Inc., Cookson Electronics and David North, as defendants, for $25.0 million . The litigation related to certain corporate activities that occurred between MacDermid and the defendants in 2006 and 2007. On April 3, 2015, the Company received part of the settlement in the amount of $16.0 million , and placed the remainder, net of legal costs, into escrow for future distribution in accordance with the pending litigation provisions of our Business Combination Agreement and Plan of Merger dated as of October 10, 2013.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Income Taxes	INCOME TAXES For the three months ended September 30, 2015 and 2014 , income tax (expense) benefit totaled $(17.6) million and $1.6 million , respectively. The Company's effective tax rate in the third quarter of 2015 was (16.89)% on pre-tax losses of $104 million , compared to an effective tax rate of (12.94)% on pre-tax income of $12.3 million in the third quarter of 2014 . The difference between the statutory and effective tax rates for the three months ended September 30, 2015 principally relates to a tax expense of $27.6 million for U.S. tax on foreign operations, a $6.4 million foreign tax rate differential and losses that did not produce tax benefits, and $16.1 million related to non-deductible transactional costs. For the nine months ended September 30, 2015 and 2014 , income tax (expense) benefit totaled $(42.0) million and $3.6 million , respectively. The Company's effective tax rate for the nine months ended September 30, 2015 was (36.53)% on pre-tax losses of $115 million , compared to an effective tax rate of (59.88)% on pre-tax income of $5.9 million for the nine months ended September 30, 2014 . The difference between the statutory and effective tax rates for the nine months ended September 30, 2015 principally relates to a tax expense for the establishment of a $21.5 million valuation allowance on foreign tax credit carryovers as a result of the impact of the Arysta Acquisition, $28.0 million for U.S. tax on foreign operations, an $11.0 million foreign rate differential and losses that did not produce tax benefits, and $17.1 million related to non-deductible transactional costs. The assessment of the need for a valuation allowance requires management to make estimates and assumptions about future earnings, reversal of existing temporary differences and available tax planning strategies. As a result of the impact of the Arysta Acquisition, the Company believes it is more likely than not that the full value of the foreign tax credit carryovers will not be realizable. Consequently, a valuation allowance of $19.0 million was recorded discretely in the first quarter of 2015. The valuation allowance was increased by $4.8 million in the second quarter and decreased by $2.3 million in the third quarter of 2015 due to changes in forecasts. The amount of unrecognized tax benefits was $68.6 million and $27.7 million at September 30, 2015 and December 31, 2014 , respectively, of which $38.1 million would reduce our effective tax rate if recognized. The increase was primarily due to the historical Arysta unrecognized tax benefits assumed. Accrued interest and penalties related to unrecognized tax benefits were $9.6 million and $4.7 million at September 30, 2015 and December 31, 2014 , respectively. The Company recognized interest and penalties of $0.4 million and $0.6 million related to unrecognized tax benefits in the income tax provision for the nine months ended September 30, 2015 and 2014 , respectively. The remainder of the increase was due to the historical Arysta interest and penalties assumed. The unrecognized tax benefits could be reduced by $3.7 million over the next 12 months as a result of the lapse of statutes of limitations in various jurisdictions. The Company is subject to U.S. Federal income tax as well as income tax in multiple state and foreign jurisdictions. The open tax years for major jurisdictions were as follows: Major Jurisdictions Open Years Belgium 2008 through current Brazil 2009 through current China 2011 through current France 2010 through current Japan 2009 through current Mexico 2009 through current South Africa 2009 through current United Kingdom 2008 through current United States 2012 through current The Company is undergoing an audit in France for tax years 2010 through 2012 and in Mexico for tax year 2013. Finally, the Company has been notified by the tax authorities of their intent to initiate an audit in Belgium for tax years 2008 through 2013.

Variable Interest Entities

Variable Interest Entities	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Variable Interest Entities	VARIABLE INTEREST ENTITIES In connection with the Arysta Acquisition in February 2015, the Company acquired ownership in two distributors deemed to be variable interest entities. Saphyto S.A. The Company holds a 45.0% interest in its product distributor, Saphyto S.A. The Company has determined that it is the primary beneficiary of the activities of Saphyto S.A., as approximately 94.0% of the distributor's sales are based on the Company's products and it has the power to direct activities impacting Saphyto S.A.'s economic performance. The Company is responsible for granting licenses to Saphyto S.A. to sell products and providing technical assistance and feedback on internal operations and controls. The Company and Saphyto's management jointly define the commercial, financial and technical strategy of Saphyto S.A., including pricing. As a result, the activities of Saphyto S.A. are consolidated in the Company's unaudited interim Condensed Consolidated Financial Statements. The following table summarizes the carrying amounts of Saphyto S.A.’s assets and liabilities included in the Company’s Condensed Consolidated Balance Sheet at September 30, 2015: (amounts in millions) September 30, Assets and Liabilities of Saphyto S.A. Cash and cash equivalents $ 0.9 Other current assets 11.7 Property, plant and equipment 1.3 Other non-current assets 0.3 Total assets $ 14.2 Current liabilities 9.8 Total liabilities $ 9.8 The capital structure of Saphyto S.A. includes total owner's equity of $4.4 million . Société des Produits Industriels et Agricoles, or SPIA The Company holds a 31.95% interest in its product distributor, SPIA. Approximately 90% of sales generated in SPIA are attributable to the Company's products. The Company is responsible for the development of SPIA's sales for export, administrative and accounting support, and technical support sales. The Company has determined that although it receives a disproportionate amount of economic benefit as compared to its ownership interest, it is not the primary beneficiary of the activities of SPIA, as the majority shareholder of SPIA holds a 50.9% interest and exercises control through voting rights. As a result, the Company has applied the equity method of accounting to its interest in SPIA and is reflected in "Other assets" in the Company's Condensed Consolidated Balance Sheet. The equity investment balance totaled $1.4 million as of September 30, 2015 , representing the Company's maximum exposure to loss. SPIA's total assets were approximately $4.6 million as of September 30, 2015 . The capital structure of SPIA includes total owner's equity of approximately $4.6 million .

Related Party Transactions

Related Party Transactions	9 Months Ended
	Sep. 30, 2015
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTY TRANSACTIONS RHSA Immediately prior to the closing of the MacDermid Acquisition, each Retaining Holder entered into a RHSA pursuant to which they agreed to exchange their respective interests in MacDermid Holdings for shares of PDH Common Stock, at an exchange rate of $11.00 per share plus, with respect to the common, class A and class B unit equity interests of MacDermid Holdings held by the Retaining Holder, (i) a proportionate share of a contingent interest in certain pending litigation, and (ii) a proportionate share of up to $100 million of contingent purchase price payable upon the attainment of certain EBITDA and stock trading price performance metrics during the seven -year period following the closing of the MacDermid Acquisition. The resulting non-controlling interest percentage for the Retaining Holders was 6.35% at September 30, 2015 and 6.67% at December 31, 2014 . Pursuant to the RHSA, until the earlier of (i) the seventh anniversary of the MacDermid Acquisition (being October 31, 2020) and (ii) such date on which all shares of PDH Common Stock held by the Retaining Holders have been converted to shares of our common stock, the Company has agreed to, among certain other covenants, obtain written consent prior to issuing additional securities, or instruments convertible, exchangeable or exercisable for securities. Advisory Services Agreement The Company is party to an Advisory Services Agreement with Mariposa Capital, LLC, an affiliate of one of our founder directors, whereby Mariposa Capital, LLC is entitled to receive an annual fee equal to $2.0 million , payable in quarterly installments. This agreement is automatically renewed for successive one -year terms unless either party notifies the other party in writing of its intention not to renew no later than 90 days prior to the expiration of the term. For each of the three month periods ended September 30, 2015 and 2014 , the Company incurred advisory fees under the agreement totaling $0.5 million , and for each of the nine month periods ended September 30, 2015 and 2014 , the Company incurred advisory fees totaling $1.5 million . Registration Rights Agreements On November 7, 2013, the Company entered into a registration rights agreement with Pershing Square on behalf of funds managed by Pershing Square pursuant to which it agreed to file a resale registration statement for the resale of the shares those funds own from time to time promptly after becoming eligible to utilize a Form S-3. The Company became eligible to file a registration statement on Form S-3 on January 23, 2015, and initially filed a registration statement on February 2, 2015 as required by this registration rights agreement. This registration statement was amended on February 12, 2015 and was declared effective on February 20, 2015.

Restructuring

Restructuring	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring	RESTRUCTURING The Company continuously evaluates all operations to identify opportunities to improve profitability by leveraging existing infrastructure to reduce operating costs and respond to overall economic conditions. Restructuring expenses were recorded in the segments as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Performance Applications $ 2.9 $ 0.6 $ 5.8 $ 1.0 Agricultural Solutions 1.6 — 12.4 — Total restructuring $ 4.5 $ 0.6 $ 18.2 $ 1.0 The restructuring plans initiated in the Performance Applications segment relate to cost saving opportunities associated with a realignment of this segment's footprint in the United States which included the sale of one of its legacy manufacturing sites during the third quarter of 2015. The restructuring plans initiated in the Agricultural Solutions segment primarily relate to cost saving opportunities associated with the integration of the Arysta, CAS and Agriphar Acquisitions. There are no material additional costs expected to be incurred related to these discrete restructuring plans. At September 30, 2015 and December 31, 2014 , restructuring liability totaled $0.3 million and $1.6 million , respectively, and are included in "Other current liabilities" in the Condensed Consolidated Balance Sheets. Restructuring expenses were recorded as follows in the Condensed Consolidated Statements of Operations: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Cost of sales $ 2.4 $ — $ 3.6 $ — Selling, technical, general and administrative 2.1 0.6 14.6 1.0 Total restructuring $ 4.5 $ 0.6 $ 18.2 $ 1.0

Segment Information

Segment Information	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Segment Information	SEGMENT INFORMATION During the first quarter of 2015, the Company completed certain changes to its organizational structure that resulted in a change to the Company's reportable business segments. As a result, the Performance Materials and Graphic Solutions reportable segments were combined into the Performance Applications reportable segment, and the AgroSolutions reportable segment was re-branded to Agricultural Solutions. The new segment reporting structure represents businesses for which separate financial information is utilized by the chief operating decision maker, or CODM, for purpose of allocating resources and evaluating performance. Each reportable segment has its own president, who reports to the CODM. The Performance Applications segment formulates and markets dynamic chemistry solutions that are used in electronics, automotive production, oil and gas production, drilling, commercial packaging and printing. Our products include surface and coating materials, water-based hydraulic control fluids and photopolymers. We sell these products worldwide. In conjunction with the sale of our products, we provide extensive technical service and support to ensure superior performance of their application. Within this segment, the Company provides specialty chemicals to the following industries; Electronics, Industrial, Offshore and Commercial Packing and Printing. For the electronics industry, we design and formulate a complete line of proprietary “wet” dynamic chemistries that our customers use to process the surface of the printed circuit boards and other electronic components they manufacture. For the industrials, our dynamic chemistries are used for finishing, cleaning and providing surface coatings for a broad range of metal and non-metal surfaces which improve the performance or look of a component of an industrial part or process. For the offshore industry, we produce water-based hydraulic control fluids for major oil companies and drilling contractors for offshore deep water production and drilling applications. For the commercial packaging and printing industries, we produce photopolymers through an extensive line of flexographic plates, used to produce printing plates for transferring images onto commercial packaging, including packaging for consumer food products, pet food bags, corrugated boxes, labels and beverage containers. In addition, we also produce photopolymer printing plates for the flexographic and letterpress newspaper and publications markets. The Agricultural Solutions segment is based on a solutions-oriented business model that focuses on product innovation to address an ever-increasing need for higher crop yield and quality. We offer a wide variety of proven plant health and pest control products to growers, which are comprised of specific target applications in the following major product lines: adjuvants; fungicides; herbicides; home applications (home and garden and ectoparasiticides); insecticides; miticides; plant growth regulators; and seed treatments. We refer to herbicides, insecticides, fungicides and seed treatment categories, based on patented or proprietary off-patent AIs, as our Global Value Added Portfolio, or GVAP. Our product portfolio also includes biosolutions (biostimulants, innovative nutrition and biocontrol), and regional off-patent AIs that complement our principal product lines. In addition, we offer certain non-crop products, including animal health products, such as honey bee protective miticides and certain veterinary vaccines. The Company evaluates the performance of its operating segments based on net sales and adjusted EBITDA. Adjusted EBITDA for each segment is calculated by taking net income and adding back interest expense, income tax expense (benefit), depreciation expense and amortization expense. This amount is further adjusted for acquisition-related expenses. Adjusted EBITDA for each segment also includes an allocation of corporate costs such as corporate salary, wages, equity compensation expense and legal costs. The following table summarizes financial information regarding each reportable segment’s results of operations for the periods presented. The historical periods have been recasted to reflect the change to the Company's reportable business segment structure during the first quarter of 2015. Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Net Sales (from external customers): Performance Applications $ 179.7 $ 196.8 $ 541.6 $ 569.6 Agricultural Solutions 417.6 — 1,265.7 — Consolidated net sales 597.3 196.8 1,807.3 569.6 Adjusted EBITDA: Performance Applications 54.5 52.4 156.9 146.5 Agricultural Solutions 60.6 — 256.3 — Adjusted EBITDA $ 115.1 $ 52.4 $ 413.2 $ 146.5 The following table reconciles Adjusted EBITDA to Net (loss) income attributable to stockholders: Three months ended September 30, Nine months ended September 30, (amounts in millions) 2015 2014 2015 2014 Adjusted EBITDA $ 115.1 $ 52.4 $ 413.2 $ 146.5 Adjustments to reconcile to net (loss) income attributable to shareholders: Interest expense (54.3 ) (8.1 ) (147.2 ) (23.8 ) Depreciation and amortization expense (62.0 ) (18.9 ) (176.3 ) (57.2 ) Restructuring and related expenses (4.5 ) (0.6 ) (18.2 ) (1.0 ) Manufacturer's profit in inventory adjustment (1.3 ) — (58.0 ) (12.0 ) Acquisition transaction costs (15.0 ) (7.7 ) (70.4 ) (18.4 ) Non-cash fair value adjustment to contingent consideration (2.7 ) (2.3 ) (6.3 ) (26.1 ) Legal settlement — — 16.0 — Acquisition put option settlement — — 3.0 — Foreign exchange loss on foreign denominated external and internal debt (33.0 ) (2.6 ) (26.8 ) (2.6 ) Fair value loss on foreign exchange forward contract (48.1 ) — (48.1 ) — Other income 1.6 0.1 4.0 0.5 Net (loss) income before income taxes and non-controlling interest $ (104.2 ) $ 12.3 $ (115.1 ) $ 5.9 Income tax (expense) benefit (17.6 ) 1.6 (42.0 ) 3.6 Net income attributable to the non-controlling interests (0.5 ) (2.0 ) (4.0 ) (5.4 ) Net (loss) income attributable to stockholders $ (122.3 ) $ 11.9 $ (161.1 ) $ 4.1

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS First Closing of OMG Acquisition On October 28, 2015, the Company completed the acquisition of the OMG Businesses, other than their Malaysian subsidiary, pursuant to the terms and conditions set forth in the merger agreement with OMG and Apollo. This transaction is the first closing of the Company's two-stage acquisition of the OMG Businesses for a total purchase price of approximately $367 million , subject to purchase price adjustments. The Company expects to complete its acquisition of the Malaysian subsidiary during the first quarter of 2016, subject to customary closing conditions, including the absence of a material adverse effect with respect to the Malaysian subsidiary. Amendment to Series B Convertible Preferred Stock On October 27, 2015, we entered into an amendment to the Arysta share purchase agreement, dated as of October 20, 2014, as amended, with Nalozo S.à.r.l. and Nalozo L.P. (as holders of at least a majority of shares of Series B Convertible Preferred Stock) to extend the maturity date of the Series B Convertible Preferred Stock from October 20, 2016 to April 20, 2017. To the extent that Nalozo S.à.r.l. and Nalozo L.P. have not converted their shares of Series B Convertible Preferred Stock into shares of our common stock by the extended maturity date, such shares of Series B Convertible Preferred Stock will be redeemed by Platform. The redemption price must be paid in shares of Platform’s common stock (valued at $27.14 per share) in the event of redemption at the extended maturity date. However, Platform may not issue more than 22,107,590 shares of its common stock in connection with a redemption at the extended maturity date. To the extent that the aggregate value of such 22,107,590 shares of Platform common stock is less than $600 million (based on a 10 -day volume weighted average price), then any shortfall would be payable in cash by Platform, subject to certain adjustments. In addition, we have agreed to (i) release certain resale restrictions on the Series B Convertible Preferred Stock, subject to a right of first offer in favor of Platform and (ii) pay Nalozo S.à.r.l. and Nalozo L.P. an aggregate cash dividend of $4.0 million per month from the original maturity date (October 20, 2016) to the extended maturity date (April 20, 2017, or such earlier date after October 20, 2016 that the then outstanding shares of Series B Convertible Preferred Stock are redeemed by Platform). Proposed Alent Acquisition Financing Syndication Process On October 28, 2015, we commenced the syndication process for (i) incremental term loans comprised of (A) U.S. dollar denominated term loans in an aggregate principal amount of approximately $1.05 billion and (B) Euro denominated term loans in an aggregate principal amount of approximately €300 million ( $330 million , based on the EURO/USD exchange rate of 1.09 on October 28, 2015), in each case, to be incurred as a new tranche of term loans under the Amended and Restated Credit Agreement, and (ii) additional revolving credit borrowings under the Amended and Restated Credit Agreement. There can be no assurance that we will be successful in our marketing efforts, or that we will be able to enter into the related incremental term loans or amendments to the Amended and Restated Credit Agreement either in the time frame currently anticipated, or on terms and with rates that are favorable to us, or at all. November Notes Offering In connection with the Alent Acquisition, on November 10, 2015, Platform completed the November Notes Offering of $500 million aggregate principal amount of senior notes due 2021. These notes are governed by an indenture dated November 10, 2015 and bear interest at a rate of 10.375% per year. The notes will mature on May 1, 2021, unless earlier redeemed. Interest is payable in cash, semi-annually in arrears on May 1 and November 1 of each year, commencing on May 1, 2016. Platform will make each interest payment to the holders of record to be determined on the immediately preceding May 1 and November 1. Concurrently with the closing of the offering, the gross proceeds from the offering (plus an additional amount from Platform necessary to provide for the special mandatory redemption price of the notes) have been deposited into an escrow account until the date on which certain escrow conditions are satisfied, including the consummation of the Alent Acquisition. The notes and the guarantees, respectively, are Platform’s and the guarantors' senior unsecured obligations and are (i) effectively subordinated to any of Platform’s and the guarantors' existing and future secured indebtedness, including existing and future secured indebtedness under the Amended and Restated Credit Agreement, to the extent of the value of the collateral securing such indebtedness; (ii) pari passu in right of payment with all of Platform's and the guarantors existing and future senior unsecured indebtedness; (iii) senior in right of payment to all of Platform's and the guarantors' existing and future subordinated indebtedness; and (iv) structurally subordinated to all of the existing and future liabilities, including trade payables, of each of Platform’s non-guarantor subsidiaries. Chief Executive Officer's Impending Retirement On October 23, 2015, our Vice Chairman of the Board, Chief Executive Officer and President, announced his intention to retire effective on the earlier to occur of (i) the date on which Platform hires a successor to his current position as Chief Executive Officer of Platform, (ii) a date that Platform elects at its sole discretion and (iii) March 31, 2016. Upon his departure, our Chief Executive Officer will be provided with all of the rights and benefits he would be entitled to receive under his existing severance agreements (all of which have previously been filed with the SEC), including (i) the Severance Letter Agreement, dated May 23, 2011, and (ii) the Letter Agreement, dated October 29, 2013, in each case, as if the separation of his employment had been due to the termination by Platform without Cause (as defined in the Severance Letter). Foreign Currency Hedges On November 5, 2015, Platform executed a series of foreign currency call and put options related to exchanging U.S. dollars (USD) for Great British Pounds (Sterling) (GBP) to further hedge the cash purchase price of Alent. The combination of the options synthetically creates a forward with a collar price of 1.56 and 1.52 USD per £1.00 for 530 million GBP.

Basis of Presentation and Sig29

Basis of Presentation and Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation These unaudited interim Condensed Consolidated Financial Statements and related information have been prepared in accordance with U.S. GAAP for interim financial information and in accordance with the applicable rules and regulations of the SEC. Accordingly, they do not include all of the disclosures required in connection with annual financial statements. These unaudited interim Condensed Consolidated Financial Statements reflect all adjustments that are, in the opinion of management, normal, recurring and necessary for a fair statement of the results of operations. These unaudited interim Condensed Consolidated Financial Statements should be read in conjunction with the Consolidated Financial Statements and the related notes thereto included in the Company’s Annual Report.
Equity Securities	Equity Securities Equity securities that have a readily determinable fair value are classified as available for sale and are carried at fair value. Unrealized holding gains and losses are recorded in other comprehensive income. Equity securities which do not have readily determinable fair values are recorded at cost and are evaluated whenever events or changes in circumstances indicate that the carrying values of such investments may be impaired.
Financial Guarantees and Factoring of Accounts Receivable	Financial Guarantees and Factoring of Accounts Receivable Guarantees provided to financial institutions on vendor and customer loans used to settle outstanding accounts receivable balances are recorded as liabilities until such time when the guarantee periods have elapsed, at which time the accounts receivable balances and the related financial guarantees are reversed. Factoring arrangements, where substantially all economic risks and rewards associated with trade receivables are transferred to a third party, are accounted for by derecognizing the trade receivables upon receipt of cash proceeds from the factoring arrangement. Factoring arrangements, whereby some, but not substantially all, economic risks and rewards are transfered to a third party and the assets subject to the factoring arrangement remain under the Company's control are accounted for by not derecognizing the trade receivables and recognizing any related obligations to the third party.
Product Registration	Product Registrations Product registrations represent external costs incurred to obtain distribution rights from regulatory bodies for certain products in our Agricultural Solutions segment. These costs include laboratory testing, legal, regulatory filing and other costs. Only costs associated with products that are probable of generating future cash flows are capitalized. The capitalized costs are amortized over the useful life of the registrations and are included in "Selling, technical, general and administrative" expenses in the Condensed Consolidated Statement of Operations and are evaluated for impairment in the same manner as other finite-lived intangible assets.
Equity Method Investments	Equity Method Investments Investments over which the Company has the ability to exercise significant influence, but which the Company does not control, are accounted for under the equity method of accounting and are included in "other assets" on the Condensed Consolidated Balance Sheet. Significant influence generally exists when the Company holds between 20% and 50% of the voting power of another entity. Investments are initially recognized at cost. The Condensed Consolidated Financial Statements include the Company's share of net earnings or losses from the date that significant influence commences until the date that significant influence ceases. When the Company's share of losses exceeds its interest in an equity investment, the carrying amount of that interest is reduced to zero, and the recognition of further losses is discontinued, except to the extent that the Company has an obligation or has made payments on behalf of the investee.
Revenue Recognition	Revenue Recognition The Company recognizes revenue, including freight charged to customers, net of applicable rebates, estimates for sales returns and allowances and discounts, when the earnings process is complete. This occurs when products have been shipped to or received by the customer, in accordance with the terms of the agreement by and between the Company and such customer, title and risk of loss has been transferred, pricing is fixed or determinable and collectability is reasonably assured. The Company allows certain distributors within the Agricultural Solutions segment one-time, non-repeatable extensions of credit on a limited portion of purchases made during a purchasing cycle, which remain in the distributor’s inventory. The extension of credit is not a right to return, and distributors must pay unconditionally when the extended credit period expires.
Accounting Policies Recently Adopted and Pending Pronouncements	Accounting Policies Recently Adopted and Pending Pronouncements Business Combinations (Topic 805) - In September 2015, the FASB issued ASU No. 2015-16 “Simplifying the Accounting for Measurement-Period Adjustments.” Under the updated guidance, an entity is no longer required to retrospectively apply adjustments to provisional amounts recorded as a part of a business combination. Adjustments to provisional amounts identified during the measurement period continue to be calculated as of the acquisition date but are recognized in the period in which they are determined, including the effects of such adjustments on earnings. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company adopted this ASU as of September 30, 2015. This ASU may have a material impact on the Company's future financial statements if material measurement period adjustments are recorded. Revenue from Contracts with Customers (Topic 606) - In August 2015, the FASB issued ASU No. 2015-14 “Deferral of the Effective Date,” which defers the effective date of ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)," for all entities by one year. As a result, the provisions of ASU No. 2014-09 will be effective prospectively for fiscal years and interim periods beginning after December 15, 2017. ASU No. 2014-09 (1) removes inconsistencies and weaknesses in revenue requirements, (2) provides a more robust framework for addressing revenue issues, (3) improves comparability of revenue recognition practices across entities, industries, jurisdictions, and capital markets, (4) provides more useful information to users of financial statements through improved disclosure requirements, and (5) simplifies the preparation of financial statements by reducing the number of requirements to which an entity must refer. The core principle of the guidance is that an entity should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. The Company continues to evaluate the impact of ASU 2014-09. Inventory (Topic 330) - In July 2015, the FASB issued ASU No. 2015-11, “ Simplifying the Measurement of Inventory.” Under the updated guidance, an entity should measure inventory at the lower of cost and net realizable value. Net realizable value is defined as the estimated selling price in the ordinary course of business, less predictable costs of completion, disposal, and transportation. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2016, with early adoption permitted. The Company adopted this ASU as of October 1, 2015 by replacing its lower of cost or market test with a lower of cost and net realizable value test. This ASU did not have a material impact on the Company's financial statements. Fair Value Measurement (Topic 820) - In May 2015, the FASB issued ASU No. 2015-07, “ Disclosures for Investments in Certain Entities That Calculate Net Asset Value per Share (or Its Equivalent).” This update eliminates diversity in practice related to investments whose fair value is measured using net asset values as a practical expedient, and removes the requirement to categorize such investments within the fair value hierarchy. The guidance is effective retrospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company continues to evaluate the impact of this new ASU, which is not expected to have a material impact on its financial statements. Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40 ) - In April 2015, the FASB issued ASU No. 2015-05, “ Customer's Accounting for Fees Paid in a Cloud Computing Arrangement.” This update provides explicit guidance to customers utilizing a cloud computing solution to help determine whether such an arrangement includes a software license, in which case the accounting applied would be similar to that of other software license arrangements. Otherwise, the arrangement would be accounted for as a service contract. The guidance is effective prospectively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company does not expect this ASU to have a material impact on its financial statements. Interest - Imputation of Interest (Subtopic 835-30) - In April 2015, the FASB issued ASU No. 2015-03, “ Simplifying the Presentation of Debt Issuance Costs.” This update eliminates the difference in the presentation of debt issuance costs and debt discount and premiums by requiring that debt issuance costs be presented as deductions from the carrying value of the related debt, in a manner similar to debt discounts. The guidance is effective retroactively for fiscal years and interim periods beginning after December 15, 2015, with early adoption permitted. The Company early adopted this ASU, and reclassified approximately $10.3 million of debt issuance costs related to term debt from assets to contra-liabilities as of December 31, 2014. Derivatives and Hedging (Topic 815) - In November 2014, the FASB issued ASU No. 2014-16, “ Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity (a consensus of the FASB Emerging Issues Task Force).” Under current practice, there were predominantly two methods used to evaluate whether the nature of the host contract in a hybrid financial instrument is more akin to debt or equity: one considered all the features including the embedded and the other excluded the embedded derivative in the consideration. This update eliminates the difference in practice by clarifying that the evaluation should be based on all the instrument’s features, including the embedded derivative, and that no single term or feature would necessarily determine the economic characteristics and risks of the host contract. The guidance is effective for fiscal years and interim periods beginning after December 15, 2015 and is applied in a modified retrospective basis to existing hybrid financial instruments issued in the form of a share as of the beginning of our fiscal year 2016. Early adoption, including in an interim period, is permitted. The Company adopted the provision of this ASU during the first quarter of 2015, with the issuance of the Series B Convertible Preferred Stock. This ASU did not have a material impact on the Company's financial statements, as there were no hybrid financial instruments requiring retrospective application.

Acquisitions of Businesses (Tab

Acquisitions of Businesses (Tables)	9 Months Ended
	Sep. 30, 2015
Business Combinations [Abstract]
Schedule of Business Acquisitions, by Acquisition	Revenues contributed by the Arysta, CAS and Agriphar Acquisitions for the three and nine months ended September 30, 2015 were as follows: (amounts in millions) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Arysta $ 318.2 $ 837.6 CAS 73.8 282.4 Agriphar 25.6 145.6 Total $ 417.6 $ 1,265.6 As the integration of the Arysta, CAS and Agriphar Acquisitions continues, discrete revenues reported by our existing businesses are being effected by the integration process and are becoming less comparable to prior periods. The Arysta, CAS and Agriphar Acquisitions had net (loss) income for the three and nine months ended September 30, 2015 as follows: (amounts in millions) Three Months Ended September 30, 2015 Nine Months Ended September 30, 2015 Arysta $ (34.8 ) $ (100.6 ) CAS (25.0 ) (52.5 ) Agriphar 3.3 25.7 Total $ (56.5 ) $ (127.4 )
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed	The following table summarizes the consideration transferred and transaction related costs incurred to acquire Arysta, CAS and Agriphar and the applicable amounts of identified assets acquired and liabilities assumed at the acquisition date: (amounts in millions) Arysta CAS Agriphar Consideration Cash, net $ 2,856.2 $ 983.1 $ 350.2 Equity Instruments 645.9 52.0 16.6 Derivative liability — — 3.5 Total Consideration $ 3,502.1 $ 1,035.1 $ 370.3 Transaction related costs $ 38.6 $ 45.4 $ 5.1 Identifiable Assets acquired and Liabilities Assumed Accounts receivable $ 674.5 $ 154.2 $ 60.1 Inventories 295.7 132.1 42.7 Other current assets 132.2 19.1 0.4 Property, plant and equipment 110.0 24.8 31.7 Identifiable intangible assets 1,638.9 534.0 183.0 Other assets 38.2 11.4 4.5 Current Liabilities (574.0 ) (69.7 ) (47.5 ) Non-current deferred tax liability (488.5 ) (26.7 ) (64.9 ) Other long term liabilities (74.2 ) (13.4 ) (9.0 ) Non-controlling interest (31.0 ) — — Total identifiable net assets 1,721.8 765.8 201.0 Goodwill 1,780.3 269.3 169.3 Total purchase price $ 3,502.1 $ 1,035.1 $ 370.3
Business Acquisition, Pro Forma Information	The following unaudited pro forma summary presents consolidated information of the Company for the three and nine months ended September 30, 2015 and 2014 , as if the Arysta Acquisition had occurred on January 1, 2014, excluding CAS and Agriphar from the 2014 results as these Acquisitions closed prior to 2015: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Revenue $ 597.3 $ 557.9 $ 1,894.7 $ 1,638.5 Net loss attributable to stockholders $ (118.6 ) $ (18.5 ) $ (160.1 ) $ (130.5 )

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2015
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	The major components of inventory were as follows: (amounts in millions) September 30, December 31, 2014 Finished goods $ 321.4 $ 156.3 Work in process 16.8 — Raw materials and supplies 128.7 49.5 Total inventory, net $ 466.9 $ 205.8

Property, Plant and Equipment (

Property, Plant and Equipment (Tables)	9 Months Ended
	Sep. 30, 2015
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment	The major components of property, plant and equipment, including equipment under capital leases, were as follows: (amounts in millions) September 30, December 31, 2014 Land and leasehold improvements $ 44.2 $ 36.6 Buildings and improvements 83.0 47.9 Machinery, equipment, fixtures and software 180.1 109.7 Assets under capital leases 8.5 5.4 315.8 199.6 Less: accumulated depreciation (57.9 ) (25.2 ) 257.9 174.4 Construction in process 9.0 4.2 Property, plant and equipment, net $ 266.9 $ 178.6

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2015
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Goodwill	The changes in the carrying amount of goodwill by segment were as follows: (amounts in millions) Performance Applications Agricultural Solutions Total December 31, 2014 $ 961.2 $ 444.1 $ 1,405.3 Addition from acquisitions — 1,697.1 1,697.1 Purchase accounting adjustments — 62.1 62.1 Foreign currency translation (58.5 ) (264.0 ) (322.5 ) September 30, 2015 $ 902.7 $ 1,939.3 $ 2,842.0
Schedule of Finite-Lived Intangible Assets	September 30, 2015 December 31, 2014 (amounts in millions) Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Gross Carrying Amount Accumulated Amortization and Foreign Exchange Net Book Value Customer lists $ 946.8 $ (157.2 ) $ 789.6 $ 613.6 $ (71.6 ) $ 542.0 Developed technology 1,867.1 (322.9 ) 1,544.2 760.5 (50.8 ) 709.7 Tradenames 19.0 (2.4 ) 16.6 19.7 (1.0 ) 18.7 Non-compete agreements 1.9 (0.4 ) 1.5 1.9 (0.1 ) 1.8 Total $ 2,834.8 $ (482.9 ) $ 2,351.9 $ 1,395.7 $ (123.5 ) $ 1,272.2

Equity Compensation Plans (Tabl

Equity Compensation Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Share-based Compensation, Restricted Stock Units Award Activity	Nine Months Ended September 30, 2015 Total RSUs Stock Options Equity Classified Liability Classified December 31, 2014 721,933 142,110 329,823 250,000 Granted 511,294 297,892 213,402 — Exercised/Issued (77,500 ) (2,500 ) — (75,000 ) Forfeited (282,545 ) (69,143 ) (213,402 ) — September 30, 2015 873,182 368,359 329,823 175,000

Pension and Post-Retirement P35

Pension and Post-Retirement Plans (Tables)	9 Months Ended
	Sep. 30, 2015
Compensation and Retirement Disclosure [Abstract]
Schedule of Net Benefit Costs	The components of net periodic pension and post-retirement benefit costs for the three and nine months ended September 30, 2015 and 2014 were as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Pension & SERP Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic (benefit) cost: Service cost $ — $ 0.2 $ — $ 0.2 $ — $ 0.6 $ — $ 0.6 Interest cost on the projected benefit obligation 1.6 0.5 1.7 0.8 4.8 1.5 5.2 2.3 Expected return on plan assets (2.4 ) (0.5 ) (2.4 ) (0.9 ) (7.2 ) (1.5 ) (7.3 ) (2.7 ) Net periodic (benefit) cost $ (0.8 ) $ 0.2 $ (0.7 ) $ 0.1 $ (2.4 ) $ 0.6 $ (2.1 ) $ 0.2 Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Post-retirement Benefits: Domestic Foreign Domestic Foreign Domestic Foreign Domestic Foreign Net periodic cost: Interest cost on the projected benefit obligation $ 0.1 $ — $ 0.1 $ — $ 0.3 $ — $ 0.3 $ — Net periodic cost $ 0.1 $ — $ 0.1 $ — $ 0.3 $ — $ 0.3 $ —

Debt, Capital Leases, Financi36

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (Tables)	9 Months Ended
	Sep. 30, 2015
Debt Disclosure [Abstract]
Schedule of Debt	The Company’s debt and capital lease obligations consisted of the following: (amounts in millions) September 30, December 31, 2014 Borrowings under lines of credit, $ 20.0 $ — USD Notes, due 2022, 1,080.3 — EUR Notes, due 2023, 384.9 — First lien secured credit facility and term loan, due 2020, 737.4 743.0 USD Incremental Loan, due 2020, 291.3 292.7 New Tranche B Term Loan, due 2020, 121.9 121.7 New Tranche B-2 Term Loan, due 2020, 481.7 — Euro Tranche Term Loan, due 2020, 225.9 246.2 New Euro Tranche Term Loan, due 2020, 89.8 — Capital lease obligations 4.3 2.0 Total debt and capital lease obligations 3,417.5 1,405.6 Less: current portion debt and capital lease obligations (16.1 ) (13.2 ) Total long-term debt and capital lease obligations $ 3,401.4 $ 1,392.4
Schedule of Maturities of Long-term Debt	Minimum principal payments on long-term debt and capital leases were as follows: (amounts in millions) Principal Payments Year ending December 31, 2015 - remaining $ 5.3 2016 20.8 2017 20.5 2018 20.4 2019 20.4 2020 1,893.6 Thereafter 1,493.4 Total $ 3,474.4

Derivative Instruments (Tables)

Derivative Instruments (Tables)	9 Months Ended
	Sep. 30, 2015
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule of Derivative Instruments in Statement of Financial Position, Fair Value	The following table summarizes the fair value of derivative instruments reported in the Condensed Consolidated Balance Sheets: (amounts in millions) September 30, December 31, 2014 Derivatives designated as hedging instruments Liabilities Balance Sheet Location Interest Rate Swaps Other current liabilities $ 18.1 $ — Derivatives not designated as hedging instruments: Assets Balance Sheet Location Foreign exchange contracts Prepaid expenses & other current assets 0.5 — Other Assets 0.7 — Liabilities Balance Sheet Location Foreign exchange contracts Other current liabilities 48.6 0.1 Total derivative contracts - Asset (Liability) $ (65.5 ) $ (0.1 )

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2015
Fair Value Disclosures [Abstract]
Fair Value, Assets Measured on Recurring Basis	The following tables present the Company’s financial instruments, assets and liabilities that are measured at fair value on a recurring basis: Fair Value Measurement Using (amounts in millions) September 30, Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 36.2 $ 36.2 $ — $ — Available for sale equity securities 6.9 6.2 0.7 — Derivatives 1.2 — 1.2 — Total $ 44.3 $ 42.4 $ 1.9 $ — Liability Category Long term contingent consideration $ 70.2 $ — $ — $ 70.2 Derivatives 66.7 — 18.6 48.1 Total $ 136.9 $ — $ 18.6 $ 118.3 Fair Value Measurement Using (amounts in millions) December 31, 2014 Quoted prices in active markets (Level 1) Significant other observable inputs (Level 2) Significant unobservable inputs (Level 3) Asset Category Money market accounts $ 15.4 $ 15.4 $ — $ — Available for sale equity securities 2.3 1.5 0.8 — Total $ 17.7 $ 16.9 $ 0.8 $ — Liability Category Long term contingent consideration $ 63.9 $ — $ — $ 63.9 Derivatives 0.1 — 0.1 — Total $ 64.0 $ — $ 0.1 $ 63.9
Fair Value Measurements, Nonrecurring	The following table presents the carrying value and estimated fair value of the Company’s long term debt and capital lease obligations: (amounts in millions) September 30, 2015 December 31, 2014 Long term debt - including current portion Carrying Value Fair Value Carrying Value Fair Value USD Notes, due 2022, interest at 6.50% $ 1,080.3 $ 935.0 $ — $ — EUR Notes, due 2023, interest at 6.00% 384.9 334.5 — — First Lien Credit Facility 737.4 712.0 743.0 721.4 USD Incremental Loan 291.3 286.6 292.7 286.0 New Tranche B Term Loan 121.9 124.2 121.7 125.2 New Tranche B-2 Term Loan 481.7 478.9 — — Euro Tranche Term Loan 225.9 218.9 246.2 245.8 New Euro Tranche Term Loan 89.8 88.9 — — Capital lease obligations 4.3 4.2 2.0 2.6 Total $ 3,417.5 $ 3,183.2 $ 1,405.6 $ 1,381.0

Accumulated Other Comprehensi39

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Schedule of Accumulated Other Comprehensive Income (Loss)	A summary of the changes in each component of accumulated other comprehensive (loss) income, net of tax for the three and nine months ended September 30, 2015 and 2014 were as follows: Three Months Ended September 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Loss Balance at June 30, 2015 $ (386.0 ) $ (15.4 ) $ 0.3 $ — $ 13.5 $ (387.6 ) Other comprehensive (loss) income before reclassifications, net (350.2 ) — 1.0 (11.8 ) 7.2 (353.8 ) Balance at September 30, 2015 $ (736.2 ) $ (15.4 ) $ 1.3 $ (11.8 ) $ 20.7 $ (741.4 ) Nine Months Ended September 30, 2015 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2014 $ (122.2 ) $ (14.9 ) $ 0.1 $ — $ 6.4 $ (130.6 ) Other comprehensive (loss) income before reclassifications, net (614.0 ) — 1.2 (11.8 ) 14.3 (610.3 ) Tax benefit reclassified — (0.5 ) — — — (0.5 ) Balance at September 30, 2015 $ (736.2 ) $ (15.4 ) $ 1.3 $ (11.8 ) $ 20.7 $ (741.4 ) Three Months Ended September 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive Income (Loss) Balance at June 30, 2014 $ 22.4 $ 2.0 $ — $ — $ (1.3 ) $ 23.1 Other comprehensive (loss) income before reclassifications, net (60.3 ) — (0.1 ) — 3.8 (56.6 ) Balance at September 30, 2014 $ (37.9 ) $ 2.0 $ (0.1 ) $ — $ 2.5 $ (33.5 ) Nine Months Ended September 30, 2014 (amounts in millions) Foreign Currency Translation Adjustments Pension and Post-retirement Plans Unrealized Gain on Available for Sale Securities Derivative Financial Instrument Revaluation Non-Controlling Interests Accumulated Other Comprehensive (loss) Income Balance at December 31, 2013 $ (0.6 ) $ 1.8 $ — $ 0.1 $ — $ 1.3 Other comprehensive (loss) income before reclassifications, net (37.3 ) 0.2 — — 2.5 (34.6 ) Reclassifications, pretax — — (0.1 ) (0.2 ) — (0.3 ) Tax expense reclassified — — — 0.1 — 0.1 Balance at September 30, 2014 $ (37.9 ) $ 2.0 $ (0.1 ) $ — $ 2.5 $ (33.5 )

Earnings Per Share (Tables)

Earnings Per Share (Tables)	9 Months Ended
	Sep. 30, 2015
Earnings Per Share [Abstract]
Schedule of Earnings Per Share, Basic and Diluted	A computation of the weighted average shares outstanding for the three and nine months ended September 30, 2015 and 2014 follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions, except per share amounts) 2015 2014 2015 2014 Net loss attributable to common stockholders $ (122.3 ) $ 11.9 $ (161.1 ) $ 4.1 Basic weighted average common stock outstanding 210.9 137.3 198.6 124.5 Number of shares contingently issuable for founder preferred share dividend rights — 11.7 — 11.7 Number of shares issuable upon conversion of founder preferred shares — 2.0 — 2.0 Number of shares contingently issuable for the contingent consideration — 1.6 — 0.4 Number of warrants — — — 1.5 Number of shares issuable upon conversion of the 401k exchange rights — — — 0.3 Number of stock options — 0.1 — 0.1 Convertible and performance-based stock — 15.4 — 16.0 Dilutive weighted average common stock outstanding 210.9 152.7 198.6 140.5 Earnings per share attributable to common stockholders: Basic $ (0.58 ) $ 0.09 $ (0.81 ) $ 0.03 Diluted $ (0.58 ) $ 0.08 $ (0.81 ) $ 0.03 For the three and nine month ended September 30, 2015 , no share adjustments are included in the dilutive weighted average shares outstanding computation as their effect would have been anti-dilutive.
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	For the three and nine months ended September 30, 2015 and 2014 , the following securities were not included in the computation of diluted shares outstanding because the effect would be anti-dilutive or because performance targets were not yet achieved for awards contingent upon performance. Three Months Ended September 30, Nine Months Ended September 30, (amounts in thousands) 2015 2014 2015 2014 Number of shares contingently issuable to Founder Entities as stock dividend to Series A Preferred Stock — — 1,652 — Number of shares issuable upon conversion of PDH Common Stock 8,207 8,775 8,207 8,775 Number of shares issuable upon conversion of Series A Preferred Stock 2,000 — 2,000 — Number of shares issuable upon conversion of Series B Convertible Preferred Stock 22,108 — 18,544 — Number of shares contingently issuable for the contingent consideration 2,496 — 1,719 1,161 Number of stock options 55 — 70 — Number of restricted stock shares and units 60 19 94 8 Number of shares issuable under the employee stock purchase plan 2 — 1 — 34,928 8,794 32,287 9,944

Operating Lease Commitments (Ta

Operating Lease Commitments (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Rent Expense	Total rental expense for operating leases was as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Rent Expense $ 6.0 $ 2.5 $ 16.4 $ 7.5
Schedule of Future Minimum Rental Payments for Operating Leases	Minimum non-cancelable operating lease commitments were as follows: (amounts in millions) Operating Lease Payment Year ending December 31, 2015, remaining $ 4.5 2016 15.0 2017 10.3 2018 6.7 2019 5.4 2020 5.5 Thereafter 18.7 $ 66.1

Contingencies, Environmental 42

Contingencies, Environmental and Legal Matters (Tables)	9 Months Ended
	Sep. 30, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Change in Asset Retirement Obligation	Changes in the Company’s AROs were as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 AROs, beginning of period $ 17.7 $ 5.4 $ 18.5 $ 4.8 Acquisitions — 0.1 0.4 0.4 Accretion expense 0.2 0.2 0.7 0.5 Remeasurements 0.5 — (0.2 ) — Payments (0.4 ) — (0.4 ) — Foreign currency adjustments (0.2 ) (0.2 ) (1.2 ) (0.2 ) AROs, end of period $ 17.8 $ 5.5 $ 17.8 $ 5.5

Income Taxes Income Taxes (Tabl

Income Taxes Income Taxes (Tables)	9 Months Ended
	Sep. 30, 2015
Income Tax Disclosure [Abstract]
Summary of Open Tax Years	The Company is subject to U.S. Federal income tax as well as income tax in multiple state and foreign jurisdictions. The open tax years for major jurisdictions were as follows: Major Jurisdictions Open Years Belgium 2008 through current Brazil 2009 through current China 2011 through current France 2010 through current Japan 2009 through current Mexico 2009 through current South Africa 2009 through current United Kingdom 2008 through current United States 2012 through current

Variable Interest Entities (Tab

Variable Interest Entities (Tables)	9 Months Ended
	Sep. 30, 2015
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Variable Interest Entities	The following table summarizes the carrying amounts of Saphyto S.A.’s assets and liabilities included in the Company’s Condensed Consolidated Balance Sheet at September 30, 2015: (amounts in millions) September 30, Assets and Liabilities of Saphyto S.A. Cash and cash equivalents $ 0.9 Other current assets 11.7 Property, plant and equipment 1.3 Other non-current assets 0.3 Total assets $ 14.2 Current liabilities 9.8 Total liabilities $ 9.8

Restructuring (Tables)

Restructuring (Tables)	9 Months Ended
	Sep. 30, 2015
Restructuring and Related Activities [Abstract]
Restructuring and Related Costs	Restructuring expenses were recorded as follows in the Condensed Consolidated Statements of Operations: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Cost of sales $ 2.4 $ — $ 3.6 $ — Selling, technical, general and administrative 2.1 0.6 14.6 1.0 Total restructuring $ 4.5 $ 0.6 $ 18.2 $ 1.0 Restructuring expenses were recorded in the segments as follows: Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Performance Applications $ 2.9 $ 0.6 $ 5.8 $ 1.0 Agricultural Solutions 1.6 — 12.4 — Total restructuring $ 4.5 $ 0.6 $ 18.2 $ 1.0

Segment Information (Tables)

Segment Information (Tables)	9 Months Ended
	Sep. 30, 2015
Segment Reporting [Abstract]
Schedule of Segment Reporting Information, by Segment	The following table summarizes financial information regarding each reportable segment’s results of operations for the periods presented. The historical periods have been recasted to reflect the change to the Company's reportable business segment structure during the first quarter of 2015. Three Months Ended September 30, Nine Months Ended September 30, (amounts in millions) 2015 2014 2015 2014 Net Sales (from external customers): Performance Applications $ 179.7 $ 196.8 $ 541.6 $ 569.6 Agricultural Solutions 417.6 — 1,265.7 — Consolidated net sales 597.3 196.8 1,807.3 569.6 Adjusted EBITDA: Performance Applications 54.5 52.4 156.9 146.5 Agricultural Solutions 60.6 — 256.3 — Adjusted EBITDA $ 115.1 $ 52.4 $ 413.2 $ 146.5 The following table reconciles Adjusted EBITDA to Net (loss) income attributable to stockholders: Three months ended September 30, Nine months ended September 30, (amounts in millions) 2015 2014 2015 2014 Adjusted EBITDA $ 115.1 $ 52.4 $ 413.2 $ 146.5 Adjustments to reconcile to net (loss) income attributable to shareholders: Interest expense (54.3 ) (8.1 ) (147.2 ) (23.8 ) Depreciation and amortization expense (62.0 ) (18.9 ) (176.3 ) (57.2 ) Restructuring and related expenses (4.5 ) (0.6 ) (18.2 ) (1.0 ) Manufacturer's profit in inventory adjustment (1.3 ) — (58.0 ) (12.0 ) Acquisition transaction costs (15.0 ) (7.7 ) (70.4 ) (18.4 ) Non-cash fair value adjustment to contingent consideration (2.7 ) (2.3 ) (6.3 ) (26.1 ) Legal settlement — — 16.0 — Acquisition put option settlement — — 3.0 — Foreign exchange loss on foreign denominated external and internal debt (33.0 ) (2.6 ) (26.8 ) (2.6 ) Fair value loss on foreign exchange forward contract (48.1 ) — (48.1 ) — Other income 1.6 0.1 4.0 0.5 Net (loss) income before income taxes and non-controlling interest $ (104.2 ) $ 12.3 $ (115.1 ) $ 5.9 Income tax (expense) benefit (17.6 ) 1.6 (42.0 ) 3.6 Net income attributable to the non-controlling interests (0.5 ) (2.0 ) (4.0 ) (5.4 ) Net (loss) income attributable to stockholders $ (122.3 ) $ 11.9 $ (161.1 ) $ 4.1

Basis of Presentation and Sig47

Basis of Presentation and Significant Accounting Policies (Details) $ / shares in Units, $ in Millions	Mar. 04, 2014	Oct. 31, 2013	Sep. 30, 2015USD ($)$ / shares	Sep. 30, 2014USD ($)	Jun. 30, 2015USD ($)	Sep. 30, 2015USD ($)segment$ / shares	Sep. 30, 2014USD ($)	Feb. 13, 2015USD ($)	Dec. 31, 2014USD ($)	Jan. 23, 2014$ / shares
Business Acquisition [Line Items]
Goodwill			$ 2,842			$ 2,842			$ 1,405.3
Share price (in usd per share) | $ / shares			$ 12.65			$ 12.65				$ 0.01
Debt issuance costs reclassification from assets to contra-liabilities									$ 10.3
Foreign currency translation adjustments			$ (350.2)	$ (60.3)		$ (614)	$ (37.3)
Number of operating segments | segment						2
Mac Dermid [Member]
Business Acquisition [Line Items]
Percentage of ownership	3.00%	97.00%
Arysta [Member]
Business Acquisition [Line Items]
Goodwill								$ 1,780.3
Prior Period Error Related To Purchase Accounting Related To Acquisitions [Member] | Restatement Adjustment [Member] | Arysta [Member]
Business Acquisition [Line Items]
Goodwill					$ 73
Foreign currency translation adjustments					$ 73

Acquisitions of Businesses (Det

Acquisitions of Businesses (Details) £ / shares in Units, £ in Millions, $ in Millions	Jul. 13, 2015GBP (£)£ / shares£ / $shares	Feb. 13, 2015USD ($)	Nov. 03, 2014USD ($)agreementshares	Oct. 01, 2014USD ($)	Oct. 01, 2014EUR (€)	Sep. 30, 2015USD ($)	Jun. 30, 2015USD ($)	Mar. 31, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)product_line	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Sep. 30, 2015MXN / $	Sep. 30, 2015BRL / $	Jul. 31, 2015GBP (£)	Jul. 31, 2015USD ($)	Jul. 13, 2015USD ($)£ / $	Jul. 10, 2015	Jun. 30, 2014USD ($)	Dec. 31, 2013USD ($)
Business Acquisition [Line Items]
Number of pence per ordinary share of acquiree | £ / shares	£ 0.503
Transaction related costs						$ 15			$ 7.7	$ 70.4	$ 18.4
Capital lease obligations						4.3				4.3		$ 2
Asset retirement obligations						17.8	$ 17.7		5.5	17.8	5.5	18.5							$ 5.4	$ 4.8
Option reversal value						(1.4)			$ 0	(19.8)	$ 0
Foreign currency exchange rate													0.0591	0.2527
Arysta [Member]
Business Acquisition [Line Items]
Total Consideration		$ 3,502.1
Cash, net		2,856.2
Common stock restricted shares (in shares)		600
Equity Instruments		645.9
Transaction related costs		$ 38.6				4.4				32.2
CAS [Member]
Business Acquisition [Line Items]
Total Consideration			$ 1,035.1
Cash, net			983.1
Equity Instruments			52
Transaction related costs			$ 45.4
Business acquisition, shares of common stock issued (in shares) | shares			2,000,000
Number of supply agreements | agreement			6
Capital lease obligations							13.2
Depreciation							$ 2.2
Asset retirement obligations						13.2				$ 13.2
Minimum supply agreement term			4 years
Major product lines | product_line										7
Preliminary estimate of its equity interest						10.1
Preliminary estimate of its equity interest after reduction						5
Purchase accounting adjustments						10.1
Goodwill, expected to be tax deductible						185				$ 185
Arysta, CAS, Agriphar [Member]
Business Acquisition [Line Items]
Goodwill acquired										$ 2,220
Agriphar [Member]
Business Acquisition [Line Items]
Total Consideration				$ 370.3	€ 300,000,000
Cash, net				350.2
Common stock restricted shares (in shares) | €					€ 711,551
Equity Instruments				16.6
Transaction related costs				$ 5.1
Option reversal value								$ (3)
Agriphar Acquisition [Member]
Business Acquisition [Line Items]
First portion of restricted stock transfer										33.33%
Second portion of restricted stock transfer										33.33%
Third portion of restricted stock transfer										33.33%
Certis Europe BV [Member] | CAS [Member]
Business Acquisition [Line Items]
Percentage equity in acquisition			15.00%
Selling, General and Administrative Expenses [Member] | Arysta [Member]
Business Acquisition [Line Items]
Transaction related costs						4.4				$ 32.2		6.4
Selling, General and Administrative Expenses [Member] | CAS [Member]
Business Acquisition [Line Items]
Transaction related costs						1.7				11.5		33.9
Selling, General and Administrative Expenses [Member] | Agriphar Acquisition [Member]
Business Acquisition [Line Items]
Transaction related costs						$ 0.1				$ 0.9		$ 4.2
Customer Lists [Member] | Arysta [Member]
Business Acquisition [Line Items]
Intangible asset useful life		20 years
Developed Technology Rights [Member] | Arysta [Member]
Business Acquisition [Line Items]
Intangible asset useful life		12 years
Cash [Member] | CAS [Member]
Business Acquisition [Line Items]
Total Consideration			$ 983
Mac Dermid [Member] | Alent [Member]
Business Acquisition [Line Items]
Acquiree shareholders number of acquiring company shares exchanged in lieu of cash	0.31523
New share issuance limited to acquiree share capital	21.90%
Acquiree share capital	£ 1,350																$ 2,100
Foreign currency exchange rate																		1.5517
Irrevocable undertaking ownership (in shares) | shares	58,432,694
Unsecured Debt [Member] | Letter of Credit [Member] | Alent [Member]
Business Acquisition [Line Items]
Revolving credit facility																	$ 1,880
Break-Up Fee [Member] | Alent [Member]
Business Acquisition [Line Items]
Break-up fee | £	£ 27
Foreign Exchange Forward [Member]
Business Acquisition [Line Items]
Foreign currency exchange rate | £ / $	1.5487																1.5487
Debt amount affected by interest rate swap															£ 1,060	$ 1,640
Percentage of forward at fixed exchange rate															50.00%	50.00%
Maximum [Member] | Developed Technology Rights [Member]
Business Acquisition [Line Items]
Intangible asset useful life										14 years
Maximum [Member] | Foreign Exchange Forward [Member]
Business Acquisition [Line Items]
Exchange rate on 50% of forward contract | £ / $	1.6244																1.6244

Acquisition of Business (Detail

Acquisition of Business (Details 2) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015
Business Acquisition [Line Items]
Revenues	$ 417.6	$ 1,265.6
Net loss attributable to stockholders	(56.5)	(127.4)
Arysta [Member]
Business Acquisition [Line Items]
Revenues	318.2	837.6
Net loss attributable to stockholders	(34.8)	(100.6)
CAS [Member]
Business Acquisition [Line Items]
Revenues	73.8	282.4
Net loss attributable to stockholders	(25)	(52.5)
Agriphar [Member]
Business Acquisition [Line Items]
Revenues	25.6	145.6
Net loss attributable to stockholders	$ 3.3	$ 25.7

Acquisitions of Businesses (D50

Acquisitions of Businesses (Details 3) € in Millions, $ in Millions	Feb. 13, 2015USD ($)	Nov. 03, 2014USD ($)	Oct. 01, 2014USD ($)	Oct. 01, 2014EUR (€)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)
Consideration
Transaction related costs					$ 15	$ 7.7	$ 70.4	$ 18.4
Identifiable Assets acquired and Liabilities Assumed
Goodwill					2,842		2,842		$ 1,405.3
Agriphar [Member]
Consideration
Cash, net			$ 350.2
Equity Instruments			16.6
Derivative liability			3.5
Total Consideration			370.3	€ 300
Transaction related costs			5.1
Identifiable Assets acquired and Liabilities Assumed
Accounts receivable			60.1
Inventories			42.7
Other current assets			0.4
Property, plant and equipment			31.7
Identifiable intangible assets			183
Other assets			4.5
Current Liabilities			(47.5)
Non-current deferred tax liability			(64.9)
Other long term liabilities			(9)
Non-controlling interest			0
Total identifiable net assets			201
Goodwill			169.3
Total purchase price			$ 370.3
Arysta [Member]
Consideration
Cash, net	$ 2,856.2
Equity Instruments	645.9
Derivative liability	0
Total Consideration	3,502.1
Transaction related costs	38.6				$ 4.4		$ 32.2
Identifiable Assets acquired and Liabilities Assumed
Accounts receivable	674.5
Inventories	295.7
Other current assets	132.2
Property, plant and equipment	110
Identifiable intangible assets	1,638.9
Other assets	38.2
Current Liabilities	(574)
Non-current deferred tax liability	(488.5)
Other long term liabilities	(74.2)
Non-controlling interest	(31)
Total identifiable net assets	1,721.8
Goodwill	1,780.3
Total purchase price	$ 3,502.1
CAS [Member]
Consideration
Cash, net		$ 983.1
Equity Instruments		52
Derivative liability		0
Total Consideration		1,035.1
Transaction related costs		45.4
Identifiable Assets acquired and Liabilities Assumed
Accounts receivable		154.2
Inventories		132.1
Other current assets		19.1
Property, plant and equipment		24.8
Identifiable intangible assets		534
Other assets		11.4
Current Liabilities		(69.7)
Non-current deferred tax liability		(26.7)
Other long term liabilities		(13.4)
Non-controlling interest		0
Total identifiable net assets		765.8
Goodwill		269.3
Total purchase price		$ 1,035.1

Acquisition of Businesses (Deta

Acquisition of Businesses (Details 4) - Arysta [Member] - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Business Acquisition [Line Items]
Revenue	$ 597.3	$ 557.9	$ 1,894.7	$ 1,638.5
Net loss attributable to stockholders	$ (118.6)	$ (18.5)	$ (160.1)	$ (130.5)

Inventories (Details)

Inventories (Details) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Inventory Disclosure [Abstract]
Finished goods	$ 321.4	$ 156.3
Work in process	16.8	0
Raw materials and supplies	128.7	49.5
Total inventory, net	$ 466.9	$ 205.8

Inventories (Details 2)

Inventories (Details 2) - Cost of Sales [Member] - Fair Value Adjustment to Inventory [Member] - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Sep. 30, 2015	Sep. 30, 2015	Sep. 30, 2014
Arysta [Member]
Inventory [Line Items]
Fair value of assets	$ 1.3	$ 37.8
CAS [Member]
Inventory [Line Items]
Fair value of assets		$ 20.2
Mac Dermid [Member]
Inventory [Line Items]
Fair value of assets			$ 12

Property, Plant and Equipment54

Property, Plant and Equipment (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 30, 2015	Dec. 31, 2014
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	$ 315.8		$ 315.8			$ 199.6
Less: accumulated depreciation	(57.9)		(57.9)			(25.2)
Construction in process	9		9			4.2
Property, plant and equipment, net	266.9		266.9			178.6
Depreciation expense	11.6	$ 4.7	33.7	$ 14
Assets acquired under capital lease	4.3		4.3			2.6
Gain (Loss) on Disposition of Property Plant Equipment	2.3
Land and Land Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	44.2		44.2			36.6
Building Improvements [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	83		83			47.9
Machinery, Equipment, Fixtures and Software [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	180.1		180.1			109.7
Assets Held under Capital Leases [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, gross	8.5		8.5			5.4
Excluding Construction in Process [Member]
Property, Plant and Equipment [Line Items]
Property, plant and equipment, net	$ 257.9		$ 257.9			$ 174.4
Performance Application's San Marcos, CA facility [Member]
Property, Plant and Equipment [Line Items]
Book value of asset held for sale					$ 10.9

Goodwill and Intangible Asset55

Goodwill and Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Indefinite-lived Intangible Assets [Line Items]
Carrying value of indefinite-lived intangible assets other than goodwill	$ 226		$ 226		$ 69.3
Intangible assets weighted average useful life			15 years
Amortization of Intangible Assets	50.4	$ 14.3	$ 143	$ 43.6
2,015	195		195
2,016	208		208
2,017	208		208
2,018	208		208
2,019	208		208
2,020	$ 206		$ 206
Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			20 years
Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			12 years
Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			20 years
Noncompete Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible assets weighted average useful life			5 years
Maximum [Member] | Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			30 years
Maximum [Member] | Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			14 years
Maximum [Member] | Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			20 years
Maximum [Member] | Noncompete Agreements [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			5 years
Minimum [Member] | Customer Relationships [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			8 years
Minimum [Member] | Developed Technology Rights [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			5 years
Minimum [Member] | Trade Names [Member]
Indefinite-lived Intangible Assets [Line Items]
Intangible asset useful life			5 years

Goodwill and Intangible Asset56

Goodwill and Intangible Assets (Details 2) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)
Goodwill [Roll Forward]
Goodwill Balance	$ 1,405.3
Goodwill Balance	2,842
Performance Materials [Member]
Goodwill [Roll Forward]
Goodwill Balance	961.2
Addition from acquisitions	0
Purchase accounting adjustments	0
Foreign currency translation	(58.5)
Goodwill Balance	902.7
Graphic Solutions [Member]
Goodwill [Roll Forward]
Goodwill Balance	444.1
Addition from acquisitions	1,697.1
Purchase accounting adjustments	62.1
Foreign currency translation	(264)
Goodwill Balance	1,939.3
ArgoSolutions [Member]
Goodwill [Roll Forward]
Goodwill Balance	1,405.3
Addition from acquisitions	1,697.1
Purchase accounting adjustments	62.1
Foreign currency translation	(322.5)
Goodwill Balance	$ 2,842

Goodwill and Intangible Asset57

Goodwill and Intangible Assets (Details 3) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,834.8	$ 1,395.7
Accumulated Amortization and Foreign Exchange	(482.9)	(123.5)
Net Book Value	2,351.9	1,272.2
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	946.8	613.6
Accumulated Amortization and Foreign Exchange	(157.2)	(71.6)
Net Book Value	789.6	542
Developed Technology Rights [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,867.1	760.5
Accumulated Amortization and Foreign Exchange	(322.9)	(50.8)
Net Book Value	1,544.2	709.7
Trade Names [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	19	19.7
Accumulated Amortization and Foreign Exchange	(2.4)	(1)
Net Book Value	16.6	18.7
Noncompete Agreements [Member]
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1.9	1.9
Accumulated Amortization and Foreign Exchange	(0.4)	(0.1)
Net Book Value	$ 1.5	$ 1.8

Goodwill and Intangible Asset58

Goodwill and Intangible Assets Goodwill and Intangible Assets (Details 4) - USD ($) $ in Millions	3 Months Ended
	Jun. 30, 2015	Sep. 30, 2015	Dec. 31, 2014
Goodwill [Line Items]
Goodwill		$ 2,842	$ 1,405.3
AFS Americas Reporting Unit [Member]
Goodwill [Line Items]
Excess of the fair value of the reporting unit over its carrying value	11.80%
Goodwill	$ 73.2
Revenue growth forecast period	5 years
Long term revenue growth rate	3.00%
WACC	10.00%
AFS Americas Reporting Unit [Member] | Minimum [Member]
Goodwill [Line Items]
Revenue growth rate	4.20%
AFS Americas Reporting Unit [Member] | Maximum [Member]
Goodwill [Line Items]
Revenue growth rate	5.60%

Equity Compensation Plans (Deta

Equity Compensation Plans (Details) $ / shares in Units, $ in Millions	Mar. 19, 2015shares	Mar. 17, 2015$ / sharesshares	Mar. 06, 2014USD ($)shares	Apr. 23, 2013shares	Sep. 30, 2015USD ($)$ / sharesshares	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)person$ / sharesshares	Sep. 30, 2014USD ($)	Jun. 30, 2015USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Combined undiscounted maximum cash value of all RSUs | $			$ 7.1		$ 5		$ 5
The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares of common stock that may be subject to grant awards (in shares)					15,500,000		15,500,000
Employee Stock Purchase Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum approved shares of common stock for ESPP (in shares)			5,178,815
Total number of shares issued under ESPP (in shares)							35,676
Persons eligible to participate | person							700
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							213,402
Canceled (in shares)							(69,143)
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised							(2,500)
Restricted Stock Units (RSUs) [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							213,402
Grant date fair value range (in usd per share) | $ / shares					$ 23.43		$ 23.43
Restricted Stock Units (RSUs) [Member] | Director [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							440,792
Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							290,250
Performance Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							209,290
Shares including multiplier of common stock issued (in shares)							40,824
Share multiplier performance period							5 years
Market Conditions [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)							74,514
Restricted Stock Units Granted 17 March 2015 [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)		7,642
Grant date fair value range (in usd per share) | $ / shares		$ 27.05
Equity compensation expense | $					$ 0.2	$ 0.1	$ 0.6	$ 0.5
Restricted Stock Units Granted 6 March 2014 [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares of common stock issued (in shares)			329,823
Equity compensation expense | $					$ (0.6)	$ 0.3	$ 0.8	$ 0.4
Minimum [Member] | Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value range (in usd per share) | $ / shares					$ 17.08		$ 17.08
Vesting period							36 months
Minimum [Member] | Performance Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share multiplier							0
Maximum [Member] | Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Grant date fair value range (in usd per share) | $ / shares					$ 27.05		$ 27.05
Vesting period							63 months 15 days
Maximum [Member] | Performance Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share multiplier							3
Deferred Bonus [Member] | Long Term Cash Bonus Plan (LTCB) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Equity compensation expense | $					$ (0.6)		$ 0.2
Allotted bonus total amount | $					$ 17		$ 17		$ 29.5
Deferred Bonus [Member] | Minimum [Member] | Long Term Cash Bonus Plan (LTCB) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							31 months
Deferred Bonus [Member] | Maximum [Member] | Long Term Cash Bonus Plan (LTCB) [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							60 months
Platform Specialty Products [Member] | Director [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Total number of shares issued under ESPP (in shares)	75,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				5 years
Option to acquire shares (in shares)				75,000
Cliff Vest [Member] | Restricted Stock Units (RSUs) [Member] | Certain Employees [Member] | The 2013 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period							24 months

Equity Compensation Plans (De60

Equity Compensation Plans (Details 2)	9 Months Ended
	Sep. 30, 2015shares
Share-based Compensation Arrangement by Share-based Payment Award, Total [Roll Forward]
Total, beginning balance (in shares)	721,933
Total, Granted (in shares)	511,294
Total, Exercised (in shares)	(77,500)
Total, Forfeited (in shares)	(282,545)
Total, ending balance (in shares)	873,182
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]
Stock Options, beginning balance (in shares)	250,000
Stock Options, Exercised (in shares)	(75,000)
Stock Options, ending balance (in shares)	175,000
Restricted Stock Units (RSUs) [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Beginning balance (in shares)	142,110
Granted (in shares)	297,892
Exercised (in shares)	2,500
Canceled (in shares)	(69,143)
Ending balance (in shares)	368,359
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]
Weighted Average Exercise Price, beginning balance (in usd per share)	329,823
Shares of common stock issued (in shares)	213,402
Weighted Average Exercise Price, Canceled (in usd per share)	(213,402)
Weighted Average Exercise Price, ending balance (in usd per share)	329,823

Pension and Post-Retirement P61

Pension and Post-Retirement Plans (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Pension Plan [Member] | Domestic [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	$ 0	$ 0	$ 0	$ 0
Other Postretirement Benefit Plan [Member] | Domestic [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost on the projected benefit obligation	100,000	100,000	300,000	300,000
Net periodic (benefit) cost	100,000	100,000	300,000	300,000
Other Postretirement Benefit Plan [Member] | Foreign [Member]
Defined Benefit Plan Disclosure [Line Items]
Interest cost on the projected benefit obligation	0	0	0	0
Net periodic (benefit) cost	0	0	0	0
Pension And SERP Benefits [Member] | Domestic [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	0	0	0	0
Interest cost on the projected benefit obligation	1,600,000	1,700,000	4,800,000	5,200,000
Expected return on plan assets	(2,400,000)	(2,400,000)	(7,200,000)	(7,300,000)
Net periodic (benefit) cost	(800,000)	(700,000)	(2,400,000)	(2,100,000)
Pension And SERP Benefits [Member] | Foreign [Member]
Defined Benefit Plan Disclosure [Line Items]
Service cost	200,000	200,000	600,000	600,000
Interest cost on the projected benefit obligation	500,000	800,000	1,500,000	2,300,000
Expected return on plan assets	(500,000)	(900,000)	(1,500,000)	(2,700,000)
Net periodic (benefit) cost	$ 200,000	$ 100,000	$ 600,000	$ 200,000

Debt, Capital Leases, Financi62

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (Details)	Feb. 13, 2015USD ($)	Feb. 13, 2015EUR (€)	Nov. 03, 2014USD ($)	Nov. 03, 2014EUR (€)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Sep. 30, 2015USD ($)	Sep. 30, 2014USD ($)	Dec. 31, 2014USD ($)	Aug. 05, 2015USD ($)	Aug. 05, 2015EUR (€)	Feb. 13, 2015EUR (€)	Feb. 02, 2015USD ($)	Feb. 02, 2015EUR (€)	Nov. 03, 2014EUR (€)	Oct. 01, 2014USD ($)
Debt Instrument [Line Items]
Weighted average interest rate, short term debt					3.26%		3.26%
Debt issuance costs reclassification from assets to contra-liabilities									$ 10,300,000
Debt issuance costs reclassification from assets to current contra-liabilities									1,900,000
Maximum percentage of letter of credit obligations exceeding revolving credit commitments					25.00%		25.00%
Voting capital stock pledged of domestic subsidiaries							100.00%
Voting capital stock pledged of non-domestic subsidiaries							65.00%
Borrowings under lines of credit, weighted average interest rate of 3.26% at September 30, 2015					$ 20,000,000		$ 20,000,000		0
Overdraft facility capacity							398,000,000		195,000,000
Factoring agreements total current capacity					250,000,000		250,000,000
Factoring agreements qualifying for sales treatment					121,400,000		121,400,000		0
Factoring agreements recorded in accounts receivable					$ (18,300,000)		$ (18,300,000)		0
First Lien Term Loan [Member]
Debt Instrument [Line Items]
Long term debt | €															€ 205,000,000
USD Incremental Loans [Member]
Debt Instrument [Line Items]
Stated interest rate					4.50%		4.50%
Spread on variable rate							3.50%
Weighted average interest rate
Long term debt					$ 291,300,000		$ 291,300,000		292,700,000
Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.50%		4.50%
Spread on variable rate							3.50%
Weighted average interest rate
Long term debt					$ 121,900,000		$ 121,900,000		121,700,000
New Tranche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	$ 500,000,000
Euro Tracnche Term Loans [Member]
Debt Instrument [Line Items]
Stated interest rate					4.25%		4.25%
Spread on variable rate							3.25%
Weighted average interest rate
Revolving credit facility | €												€ 287,000,000
Long term debt					$ 225,900,000		$ 225,900,000		246,200,000
Multicurrency revolving credit facility was increase | €		€ 83,000,000
Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.75%		4.75%
Spread on variable rate							3.75%
Weighted average interest rate
Long term debt					$ 481,700,000		$ 481,700,000		0
Euro Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.25%		4.25%
Spread on variable rate							3.25%
Weighted average interest rate
Long term debt					$ 89,800,000		$ 89,800,000		0
Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility	163,000,000
Multicurrency revolving credit facility was increase	75,000,000
Borrowed under U.S. Dollar revolving credit facility for acquisition	160,000,000
Outstanding letters of credit					$ 26,600,000		26,600,000		1,000,000
Reduction in borrowings							$ 1,900,000		1,000,000
Revolving Credit Facility, Multi Currency [Member]
Debt Instrument [Line Items]
Revolving credit facility	163,000,000
Multicurrency revolving credit facility was increase	$ 75,000,000
Eurodollar [Member] | Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	3.50%	3.50%
Eurodollar [Member] | Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	3.75%	3.75%
Eurodollar [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate	3.00%	3.00%
Base Rate [Member] | Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	2.50%	2.50%
Base Rate [Member] | Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Spread on variable rate	2.75%	2.75%
Base Rate [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Spread on variable rate	2.00%	2.00%
Maximum [Member]
Debt Instrument [Line Items]
Ratio of debt to EBITDA							1
Maximum [Member] | Overdraft Facility [Member]
Debt Instrument [Line Items]
Stated interest rate					11.35%		11.35%
Minimum [Member]
Debt Instrument [Line Items]
Ratio of debt to EBITDA							6.5
Minimum [Member] | Overdraft Facility [Member]
Debt Instrument [Line Items]
Stated interest rate					0.45%		0.45%
Barclays Bank PLC [Member]
Debt Instrument [Line Items]
Second amendment increase in credit facility																$ 300,000,000
Chemtura [Member] | New Tranche B Term Loans [Member]
Debt Instrument [Line Items]
Long term debt			$ 130,000,000
Chemtura [Member] | Revolving Credit Facility [Member]
Debt Instrument [Line Items]
Revolving credit facility			87,500,000
Borrowed under the U.S. Dollar and multicurrency revolving credit facility			60,000,000	€ 55,000,000
Chemtura [Member] | Revolving Credit Facility, Multi Currency [Member]
Debt Instrument [Line Items]
Revolving credit facility			$ 87,500,000
Arysta [Member] | New Tranche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	$ 500,000,000
Original issue discount percentage	$ 0.01
Arysta [Member] | Euro Tracnche Term Loans [Member]
Debt Instrument [Line Items]
Original issue discount percentage | €												0.02
Increase in Euro tranche term loan facility | €												€ 83,000,000
Notes Payable to Banks [Member] | USD Notes [Member]
Debt Instrument [Line Items]
Stated interest rate					6.50%		6.50%						6.50%	6.50%
Long term debt					$ 1,080,300,000		$ 1,080,300,000		0
Gross debt, long term													$ 1,100,000,000
Notes Payable to Banks [Member] | Euro Notes [Member]
Debt Instrument [Line Items]
Stated interest rate					6.00%		6.00%						6.00%	6.00%
Long term debt					$ 384,900,000		$ 384,900,000		0
Gross debt, long term | €														€ 350,000,000
Original issue premium													$ 1,000,000
Secured Debt [Member] | First Lien Term Loan [Member]
Debt Instrument [Line Items]
Stated interest rate					4.50%		4.50%
Spread on variable rate							3.50%
Weighted average interest rate
Long term debt					$ 737,400,000		$ 737,400,000		743,000,000
Other Operating Income (Expense) [Member]
Debt Instrument [Line Items]
Factoring agreement program gains						$ (500,000)	(1,500,000)	$ 0
Factoring fees					(100,000)	$ 0	(100,000)	$ 0
Financial Guarantee [Member]
Debt Instrument [Line Items]
Financial guarantees					$ 40,700,000		$ 40,700,000		$ 0
Interest Rate Swap [Member] | Notes Payable to Banks [Member] | USD Notes [Member]
Debt Instrument [Line Items]
Debt amount affected by interest rate swap										$ 1,160,000,000
Interest rate swap rate										1.96%	1.96%
Interest Rate Swap [Member] | Notes Payable to Banks [Member] | Euro Notes [Member]
Debt Instrument [Line Items]
Debt amount affected by interest rate swap | €											€ 285,000,000
Interest rate swap rate										1.20%	1.20%

Debt, Capital Leases, Financi63

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (Details 2) € in Millions, $ in Millions	Sep. 30, 2015USD ($)	Dec. 31, 2014USD ($)	Nov. 03, 2014EUR (€)
Debt Instrument [Line Items]
Borrowings under lines of credit, weighted average interest rate of 3.26% at September 30, 2015	$ 20	$ 0
Capital lease obligations	4.3	2
Long-Term Debt And Debt Issuance Costs, Gross	3,417.5	1,405.6
Less: current portion debt and capital lease obligations	(16.1)	(13.2)
Total long-term debt and capital lease obligations	3,401.4	1,392.4
USD Notes [Member] | Notes Payable to Banks [Member]
Debt Instrument [Line Items]
Long term debt	1,080.3	0
Euro Notes [Member] | Notes Payable to Banks [Member]
Debt Instrument [Line Items]
Long term debt	384.9	0
First Lien Term Loan [Member]
Debt Instrument [Line Items]
Long term debt | €			€ 205
First Lien Term Loan [Member] | Secured Debt [Member]
Debt Instrument [Line Items]
Long term debt	737.4	743
USD Incremental Loans [Member]
Debt Instrument [Line Items]
Long term debt	291.3	292.7
Tranche B Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	121.9	121.7
Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	481.7	0
Euro Tracnche Term Loans [Member]
Debt Instrument [Line Items]
Long term debt	225.9	246.2
Euro Traunche B-2 Term Loan [Member]
Debt Instrument [Line Items]
Long term debt	$ 89.8	$ 0

Debt, Capital Leases, Financi64

Debt, Capital Leases, Financial Guarantees and Factoring Arrangements (Details 3) $ in Millions	Sep. 30, 2015USD ($)
Debt Disclosure [Abstract]
2015 - remaining	$ 5.3
2,016	20.8
2,017	20.5
2,018	20.4
2,019	20.4
2,020	1,893.6
Thereafter	1,493.4
Total	$ 3,474.4

Derivative Instruments (Details

Derivative Instruments (Details) € in Millions, £ in Millions

3 Months Ended

9 Months Ended

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Sep. 30, 2015GBP (£)

Sep. 30, 2015USD ($)

Sep. 30, 2015MXN / $

Sep. 30, 2015BRL / $

Aug. 05, 2015USD ($)

Aug. 05, 2015EUR (€)

Jul. 31, 2015GBP (£)

Jul. 31, 2015USD ($)

Jul. 13, 2015£ / $

Derivative Instruments, Gain (Loss) [Line Items]

Derivative financial instruments revaluation, net of tax

$ (47,300,000)

$ (2,600,000)

$ (49,900,000)

$ (2,200,000)

Foreign currency exchange rate

0.0591

0.2527

Foreign Exchange Forward [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Debt amount affected by interest rate swap

£ 1,060

$ 1,640,000,000

Foreign currency exchange rate | £ / $

1.5487

Percentage of forward at fixed exchange rate

50.00%

50.00%

Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Foreign currency forward contract

$ 910,000,000

Foreign Exchange Contract [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Derivative financial instruments revaluation, net of tax

(47,300,000)

(2,600,000)

(49,900,000)

(2,200,000)

Foreign Exchange Contract [Member] | Designated as Hedging Instrument [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Unrealized gains (losses) recorded to other comprehensive income related to foreign currency hedges

$ 18,100,000

$ 0

$ 18,100,000

$ 200,000

United States of America, Dollars [Member] | Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Foreign currency forward contract | £

£ 533

United Kingdom, Pounds [Member] | Foreign Exchange Forward [Member] | Not Designated as Hedging Instrument [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Foreign currency forward contract

$ 99,800,000

Maximum [Member] | Foreign Exchange Forward [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Exchange rate on 50% of forward contract | £ / $

1.6244

USD Notes [Member] | Notes Payable to Banks [Member] | Interest Rate Swap [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Debt amount affected by interest rate swap

$ 1,160,000,000

Interest rate swap rate

1.96%

1.96%

Euro Notes [Member] | Notes Payable to Banks [Member] | Interest Rate Swap [Member]

Derivative Instruments, Gain (Loss) [Line Items]

Debt amount affected by interest rate swap | €

€ 285

Interest rate swap rate

1.20%

1.20%

Derivative Instruments (Detai66

Derivative Instruments (Details 2) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Derivative Instruments, Gain (Loss) [Line Items]
Total derivative contracts	$ (65.5)	$ (0.1)
Other Current Liabilities [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts, liability, current	48.6	0.1
Other Current Liabilities [Member] | Interest Rate Swap [Member] | Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts, liability, current	18.1	0
Prepaid Expenses and Other Current Assets [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts, current	0.5	0
Other Assets [Member] | Foreign Exchange Contract [Member] | Not Designated as Hedging Instrument [Member]
Derivative Instruments, Gain (Loss) [Line Items]
Foreign exchange contracts, noncurrent	$ 0.7	$ 0

Fair Value Measurements (Detail

Fair Value Measurements (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
NAV Redemptions			$ 1
Non-cash fair value adjustment to contingent consideration	$ (2,700,000)	$ (2,300,000)	$ (6,300,000)	$ (26,100,000)
Percentage change in rate affecting component measurement			1.00%
Measurement component change affected by change in discount rate			$ 2,000,000
Mac Dermid [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term contingent consideration	100,000,000		$ 100,000,000
Price performance metrics period			7 years
EBITDA related earnout include a discount rate			1.50%
Business acquisition expected future value payments			$ 60,000,000
Selling, General and Administrative Expenses [Member] | Mac Dermid [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Non-cash fair value adjustment to contingent consideration	$ 2,700,000	$ 2,300,000	$ 6,300,000	$ 26,100,000

Fair Value Measurements (Deta68

Fair Value Measurements (Details 2) - Fair Value, Measurements, Recurring [Member] - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Estimate of Fair Value Measurement [Member]
Asset Category
Money market accounts	$ 36.2	$ 15.4
Available for sale equity securities	6.9	2.3
Derivatives	1.2
Total	44.3	17.7
Liability Category
Long term contingent consideration	70.2	63.9
Derivatives	66.7	0.1
Total	136.9	64
Fair Value, Inputs, Level 1 [Member]
Asset Category
Money market accounts	36.2	15.4
Available for sale equity securities	6.2	1.5
Derivatives	0
Total	42.4	16.9
Liability Category
Long term contingent consideration	0	0
Derivatives	0	0
Total	0	0
Fair Value, Inputs, Level 2 [Member]
Asset Category
Money market accounts	0	0
Available for sale equity securities	0.7	0.8
Derivatives	1.2
Total	1.9	0.8
Liability Category
Long term contingent consideration	0	0
Derivatives	18.6	0.1
Total	18.6	0.1
Fair Value, Inputs, Level 3 [Member]
Asset Category
Money market accounts	0	0
Available for sale equity securities	0	0
Derivatives	0
Total	0	0
Liability Category
Long term contingent consideration	70.2	63.9
Derivatives	48.1	0
Total	$ 118.3	$ 63.9

Fair Value Measurements (Deta69

Fair Value Measurements (Details 3) € in Millions, $ in Millions	Sep. 30, 2015USD ($)	Feb. 02, 2015USD ($)	Feb. 02, 2015EUR (€)	Dec. 31, 2014USD ($)	Nov. 03, 2014EUR (€)
Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Capital lease obligations	$ 4.3			$ 2
Long term debt	3,417.5			1,405.6
Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Capital lease obligations	4.2			2.6
Long term debt	$ 3,183.2			1,381
First Lien Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt | €					€ 205
USD Incremental Loans [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Long term debt	$ 291.3			292.7
USD Incremental Loans [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	291.3			292.7
USD Incremental Loans [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 286.6			286
Tranche B Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Long term debt	$ 121.9			121.7
Tranche B Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	121.9			121.7
Tranche B Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 124.2			125.2
Traunche B-2 Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.75%
Long term debt	$ 481.7			0
Traunche B-2 Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	481.7			0
Traunche B-2 Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 478.9			0
Euro Tracnche Term Loans [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Long term debt	$ 225.9			246.2
Euro Tracnche Term Loans [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	225.9			246.2
Euro Tracnche Term Loans [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 218.9			245.8
Euro Traunche B-2 Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.25%
Long term debt	$ 89.8			0
Euro Traunche B-2 Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	89.8			0
Euro Traunche B-2 Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 88.9			0
Notes Payable to Banks [Member] | USD Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.50%	6.50%	6.50%
Gross debt, long term		$ 1,100
Long term debt	$ 1,080.3			0
Notes Payable to Banks [Member] | USD Notes [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	1,080.3			0
Notes Payable to Banks [Member] | USD Notes [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	$ 935			0
Notes Payable to Banks [Member] | Euro Notes [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	6.00%	6.00%	6.00%
Gross debt, long term | €			€ 350
Long term debt	$ 384.9			0
Notes Payable to Banks [Member] | Euro Notes [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	384.9			0
Notes Payable to Banks [Member] | Euro Notes [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Gross debt, long term	$ 334.5			0
Secured Debt [Member] | First Lien Term Loan [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Debt Instrument, Interest Rate, Stated Percentage	4.50%
Long term debt	$ 737.4			743
Secured Debt [Member] | First Lien Term Loan [Member] | Reported Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	737.4			743
Secured Debt [Member] | First Lien Term Loan [Member] | Estimate of Fair Value Measurement [Member]
Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]
Long term debt	$ 712			$ 721.4

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Jun. 29, 2015	Jun. 23, 2015	Mar. 19, 2015	Feb. 25, 2015	Feb. 13, 2015	Dec. 31, 2014	May. 22, 2013	Apr. 23, 2013	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Jun. 13, 2014	Jan. 23, 2014	Jan. 05, 2014
Class of Stock [Line Items]
Price of shares issued (in usd per share)										$ 26.50			$ 19	$ 11					$ 11
Issuance of common shares to directors for exercise of stock options (in shares)															75,000
Proceeds from Issuance of Common Stock	$ 483,000,000														$ 469,500,000	$ 473,400,000
Number of preferred shares authorized in amendment (in shares)																	5,000,000
Liquidation preference per share									$ 1,000						$ 1,000
Share price (in usd per share)									$ 12.65						12.65			$ 0.01
Preferred stock outstanding (in shares)										$ 0	$ 0	$ (400,000)	$ 300,200,000	$ 0
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14						10,050,290
Dividend price (in usd per share)						$ 22.85
Total number of shares of common stock originally issuable upon the exchange of PDH common stock pursuant to the RHSA (in shares)									8,800,000
Net income allocated to Retaining Holders												$ 2,100,000
Conversion price (in usd per share)									$ 27.14						$ 27.14
Whole payment amount									$ 320,000,000						$ 320,000,000
Arysta [Member]
Class of Stock [Line Items]
Volume weighted average price period					10 days
Equity Instruments					$ 645,900,000
Noncontrolling interest acquired					$ 31,000,000
Maximum share conversion (in shares)				22,107,590	22,107,590
Mac Dermid [Member]
Class of Stock [Line Items]
Equity Instruments									97,500,000						97,500,000
Net income allocated to Retaining Holders									$ (1,100,000)						$ 100,000	$ 5,200,000
Noncontrolling interest percentage						6.67%			6.35%			6.76%			6.35%	6.76%
Platform Specialty Products [Member] | Director [Member]
Class of Stock [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period								5 years
Option to acquire shares (in shares)								75,000
Option exercised to acquire shares (in shares)			75,000
PDH [Member]
Class of Stock [Line Items]
Rate PDH Common stock that may be exchanged for shares of common stock															25.00%
Common stock issued in connection with exchange of PDH common stock (in shares)									567,920						567,920
Weighted Average [Member]
Class of Stock [Line Items]
Share price (in usd per share)						$ 23.16
Redeemable Series B Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity designated (in shares)									600,000						600,000
Temporary equity issued (in shares)						0			600,000						600,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Number of preferred shares authorized in amendment (in shares)																	2,000,000
Preferred shares, shares issued (in shares)						2,000,000			2,000,000						2,000,000
Preferred shares, shares outstanding (in shares)						2,000,000			2,000,000						2,000,000
Series A Preferred Stock [Member] | Founders Entities [Member]
Class of Stock [Line Items]
Preferred stock outstanding (in shares)							$ 2,000,000
Common Stock [Member]
Class of Stock [Line Items]
Issuance of stock, shares (in Shares)		18,226,414							6,343	406,217	21,316		15,800,000	3,959
Price of shares issued (in usd per share)		$ 26.50
Issuance of common shares to directors for exercise of stock options (in shares)									2,500		75,000
Payments of Stock Issuance Costs	$ 14,800,000
Preferred stock outstanding (in shares)													$ 200,000
Issuance of common stock to Founder Entities as stock dividend to Series A Preferred Stock declared on 12/31/14											10,050,290
Common Stock [Member] | Underwriter Options [Member]
Class of Stock [Line Items]
Issuance of common shares to directors for exercise of stock options (in shares)		2,377,358
Series A Preferred Stock To Common Stock [Member]
Class of Stock [Line Items]
Preferred Stock To Common Stock Conversion Ratio															1

Accumulated Other Comprehensi71

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	$ (387.6)	$ 23.1	$ (130.6)	$ 1.3
Other comprehensive (loss) income before reclassifications, net	(353.8)	(56.6)	(610.3)	(34.6)
Reclassifications, pretax				(0.3)
Tax benefit reclassified			(0.5)	0.1
Ending balance	(741.4)	(33.5)	(741.4)	(33.5)
Accumulated Translation Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(386)	22.4	(122.2)	(0.6)
Other comprehensive (loss) income before reclassifications, net	(350.2)	(60.3)	(614)	(37.3)
Reclassifications, pretax				0
Tax benefit reclassified			0	0
Ending balance	(736.2)	(37.9)	(736.2)	(37.9)
Accumulated Defined Benefit Plans Adjustment [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	(15.4)	2	(14.9)	1.8
Other comprehensive (loss) income before reclassifications, net	0	0	0	0.2
Reclassifications, pretax				0
Tax benefit reclassified			(0.5)	0
Ending balance	(15.4)	2	(15.4)	2
Accumulated Net Unrealized Investment Gain (Loss) [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	0.3	0	0.1	0
Other comprehensive (loss) income before reclassifications, net	1	(0.1)	1.2	0
Reclassifications, pretax				(0.1)
Tax benefit reclassified			0	0
Ending balance	1.3	(0.1)	1.3	(0.1)
Accumulated Net Gain (Loss) from Designated or Qualifying Cash Flow Hedges [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	0	0	0	0.1
Other comprehensive (loss) income before reclassifications, net	(11.8)	0	(11.8)	0
Reclassifications, pretax				(0.2)
Tax benefit reclassified			0	0.1
Ending balance	(11.8)	0	(11.8)	0
Noncontrolling Interest [Member]
Accumulated Other Comprehensive Income (Loss), Net of Tax [Roll Forward]
Beginning balance	13.5	(1.3)	6.4	0
Other comprehensive (loss) income before reclassifications, net	7.2	3.8	14.3	2.5
Reclassifications, pretax				0
Tax benefit reclassified			0	0
Ending balance	$ 20.7	$ 2.5	$ 20.7	$ 2.5

Earnings Per Share (Details) -

Earnings Per Share (Details) - Weighted Average Shares Outstanding - USD ($) $ / shares in Units, shares in Millions, $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Earnings Per Share [Abstract]
Net income attributable to common shareholders (in Dollars)	$ (122.3)	$ 11.9	$ (161.1)	$ 4.1
Basic weighted average common shares outstanding (in shares)	210.9	137.3	198.6	124.5
Number of shares contingently issuable for founder preferred share dividend rights (in shares)	0	11.7	0	11.7
Number of shares issuable upon conversion of founder preferred shares (in shares)	0	2	0	2
Number of shares contingently issuable for the contingent consideration (in shares)	0	1.6	0	0.4
Number of warrants (in shares)	0	0	0	1.5
Number of shares issuable upon conversion of the 401k exchange rights (in shares)	0	0	0	0.3
Number of stock options (in shares)	0	0.1	0	0.1
share adjustments (in shares)	0	15.4	0	16
Dilutive weighted average common shares outstanding (in shares)	210.9	152.7	198.6	140.5
Basic (in usd per share)	$ (0.58)	$ 0.09	$ (0.81)	$ 0.03
Diluted (in usd per share)	$ (0.58)	$ 0.08	$ (0.81)	$ 0.03

Earnings Per Share (Details 2)

Earnings Per Share (Details 2) - shares shares in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	34,928	8,794	32,287	9,944
Contingently Issuable Shares For The Founder Preferred Share Dividend Right [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	0	0	1,652	0
Shares Issuable Upon Conversion of PDH Non-controlling Interest [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	8,207	8,775	8,207	8,775
Shares Issuable Upon Conversion Of Founder Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	2,000	0	2,000	0
Shares Issuable Upon Conversion Of Series B Preferred Shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	22,108	0	18,544	0
Contingently Issuable for the Contingent Consideration [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	2,496	0	1,719	1,161
Equity Option [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	55	0	70	0
Restricted Stock Units (RSUs) [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	60	19	94	8
Shares Issuable Under Employee Stock Purchase Plan [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Weighted-average securities not included in computation of diluted shares outstanding (in shares)	2	0	1	0

Operating Lease Commitments (De

Operating Lease Commitments (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Commitments and Contingencies Disclosure [Abstract]
Total rent expense	$ 6	$ 2.5	$ 16.4	$ 7.5
2015, remaining	4.5		4.5
2,016	15		15
2,017	10.3		10.3
2,018	6.7		6.7
2,019	5.4		5.4
2,020	5.5		5.5
Thereafter	18.7		18.7
Total	$ 66.1		$ 66.1

Contingencies, Environmental 75

Contingencies, Environmental and Legal Matters (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Loss Contingency Accrual [Roll Forward]
AROs, beginning of period	$ 17.7	$ 5.4	$ 18.5	$ 4.8
Acquisitions	0	0.1	0.4	0.4
Accretion expense	0.2	0.2	0.7	0.5
Remeasurements	0.5	0	(0.2)	0
Payments	(0.4)	0	(0.4)	0
Foreign currency adjustments	(0.2)	(0.2)	(1.2)	(0.2)
AROs, end of period	$ 17.8	$ 5.5	$ 17.8	$ 5.5

Contingencies, Environmental 76

Contingencies, Environmental and Legal Matters (Details 2) MXN in Millions, BRL in Millions, $ in Millions

Apr. 03, 2015USD ($)

Feb. 25, 2015shares

Feb. 19, 2015USD ($)

Feb. 13, 2015USD ($)shares

Apr. 30, 2014USD ($)defendant

Nov. 30, 2011defendant

Jun. 30, 2009defendant

Sep. 30, 2015USD ($)

Sep. 30, 2014USD ($)

Sep. 30, 2015USD ($)employeedefendant

Sep. 30, 2015BRLemployeedefendant

Sep. 30, 2014USD ($)

Dec. 31, 2014USD ($)

Dec. 31, 2014MXN

Sep. 30, 2015MXN / $

Sep. 30, 2015BRL / $

Sep. 30, 2015BRL

Jun. 30, 2015USD ($)

Jun. 30, 2014USD ($)

Dec. 31, 2013USD ($)

Loss Contingencies [Line Items]

Asset retirement obligations

$ 17.8

$ 5.5

$ 17.8

$ 5.5

$ 18.5

$ 17.7

$ 5.4

$ 4.8

Reserves for environmental matters

1.7

1.7

4.5

Estimate of possible loss in legal proceedings

6.6

6.6

4.4

Potential litigation loss exchange rate

0.0591

0.2527

Contest of tax assessment

10.6

10.6

BRL 41.8

Legal settlement

$ 0

$ 0

16

$ 0

Settled Litigation [Member]

Loss Contingencies [Line Items]

Legal settlement

$ 25

Amount awarded

$ 16

Arysta [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of defendants | defendant

6

26

Compensation sought

12.6

BRL 50

Remediation amount sought

$ 17.9

BRL 70.9

Agricola Colonet, SA de CV [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Compensation sought

$ 10.7

MXN 181

Arysta [Member]

Loss Contingencies [Line Items]

Series B preferred stock issued (in shares)

$ 600

Maximum share conversion (in shares) | shares

22,107,590

22,107,590

Volume weighted average price period

10 days

Arysta [Member] | Series B Preferred Stock [Member]

Loss Contingencies [Line Items]

Series B preferred stock issued (in shares)

$ 600

Health Problems From Employment Site [Member] | Arysta [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of defendants | defendant

80

80

Compensation sought

$ 43.8

BRL 173.3

Number of former employees | employee

13

13

Health Risk From Product Exposure [Member] | Arysta LifeScience North America, LLC [Member] | Pending Litigation [Member]

Loss Contingencies [Line Items]

Number of defendants | defendant

30

Compensation sought

$ 13.2

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended			9 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Mar. 31, 2015	Dec. 31, 2014
Interim Period, Costs Not Allocable [Line Items]
Income tax (expense) benefit	$ (17.6)		$ 1.6	$ (42)	$ 3.6
Effective income tax rate	(16.89%)		(12.94%)	(36.53%)	(59.88%)
(Loss) income before income taxes and non-controlling interests	$ (104.2)		$ 12.3	$ (115.1)	$ 5.9
U.S. tax on foreign operations	27.6			(28)
Foreign tax rate differential and losses	6.4			11
Non-deductible transactional costs	16.1			17.1
Tax charge due to change in valuation allowance	(2.3)	$ 4.8
Unrecognized tax benefit	68.6			68.6			$ 27.7
Reduction in effective tax rate	38.1			38.1
Accrued interest and penalties related to unrecognized tax benefits	9.6			9.6			$ 4.7
Interest and penalties recognized				0.4	0.6
Possible reduction in tax benefits from lapse of applicable statute of limitations	$ 3.7			$ 3.7
State and Local Jurisdiction [Member]
Interim Period, Costs Not Allocable [Line Items]
Valuation allowance						$ 19
Arysta [Member]
Interim Period, Costs Not Allocable [Line Items]
Valuation allowance on foreign tax credit carryovers			$ 21.5		$ 21.5

Income Taxes Income Taxes (Deta

Income Taxes Income Taxes (Details 2) - Earliest Tax Year [Member]	9 Months Ended
	Sep. 30, 2015
Administration of the Treasury, Belgium [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,008
Secretariat of the Federal Revenue Bureau of Brazil [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
State Administration of Taxation, China [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,011
Ministry of the Economy, Finance and Industry, France [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,010
National Tax Agency, Japan [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
Mexican Tax Authority [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
South Africa Revenue Service (SARS) [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,009
Her Majesty's Revenue and Customs (HMRC) [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,008
Internal Revenue Service (IRS) [Member]
Income Tax Examination [Line Items]
Open Tax Year	2,012

Variable Interest Entities (Det

Variable Interest Entities (Details) $ in Millions	9 Months Ended
	Sep. 30, 2015USD ($)	Feb. 28, 2015	Dec. 31, 2014USD ($)
Variable Interest Entity [Line Items]
Number of VIE's		2
Total assets	$ 8,075.8		$ 4,547.3
Variable Interest Entity, Primary Beneficiary [Member] | Subsidiaries [Member]
Variable Interest Entity [Line Items]
Interest in entity	45.00%
Variable Interest Entity, Primary Beneficiary [Member] | Saphyto S.A. [Member]
Variable Interest Entity [Line Items]
Equity of equity method investee	$ 4.4
Total assets	$ 14.2
Variable Interest Entity, Primary Beneficiary [Member] | Saphyto S.A. [Member] | Sale Of Platform Products [Member] | Product Concentration Risk [Member]
Variable Interest Entity [Line Items]
Percentage of sales that are Platform products	94.00%
Variable Interest Entity, Not Primary Beneficiary [Member] | Minority Shareholder Of SPIA [Member]
Variable Interest Entity [Line Items]
Interest in entity	50.90%
Variable Interest Entity, Not Primary Beneficiary [Member] | SPIA [Member]
Variable Interest Entity [Line Items]
Ownership percentage of equity investment	31.95%
Equity of equity method investee	$ 4.6
Equity method investment on balance sheet	1.4
Total assets	$ 4.6
Variable Interest Entity, Not Primary Beneficiary [Member] | SPIA [Member] | Sale Of Platform Products [Member] | Product Concentration Risk [Member]
Variable Interest Entity [Line Items]
Percentage of sales that are Platform products	90.00%

Variable Interest Entities (D80

Variable Interest Entities (Details 2) - USD ($) $ in Millions	Sep. 30, 2015	Dec. 31, 2014
Variable Interest Entity [Line Items]
Property, plant and equipment, net	$ 266.9	$ 178.6
Other assets	76.3	45.4
Total assets	8,075.8	4,547.3
Current liabilities	965.1	240.7
Total liabilities	5,161.6	$ 1,994.7
Variable Interest Entity, Primary Beneficiary [Member] | Saphyto S.A. [Member]
Variable Interest Entity [Line Items]
Cash and cash equivalents	0.9
Other current assets	11.7
Property, plant and equipment, net	1.3
Other assets	0.3
Total assets	14.2
Current liabilities	9.8
Total liabilities	$ 9.8

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Mac Dermid [Member]
Related Party Transaction [Line Items]
Price exchange rate (in usd per share)	$ 11		$ 11
Contingent purchase payable	$ 100,000,000		$ 100,000,000
Price performance metrics period			7 years
Noncontrolling interest percentage	6.35%	6.76%	6.35%	6.76%	6.67%
Mariposa Capital [Member]
Related Party Transaction [Line Items]
Automatic renewal period			1 year
Agreement renewal period			90 days
Advisory fees	$ 500,000	$ 500,000	$ 1,500,000	$ 1,000,000
Annual Fees [Member] | Mariposa Capital [Member]
Related Party Transaction [Line Items]
Annual fee			$ 2,000,000

Restructuring (Details)

Restructuring (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014	Dec. 31, 2014
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	$ 4.5	$ 0.6	$ 18.2	$ 1
Cost of Sales [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	2.4	0	3.6	0
Selling, Technical, General And Administrative [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	2.1	0.6	14.6	1
Performance Applications [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	2.9	0.6	5.8	1
Agricultural Solutions [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring expenses	1.6	$ 0	12.4	$ 0
Other Current Liabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring liabilities	$ 0.3		$ 0.3		$ 1.6

Segment Information (Details)

Segment Information (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Net Sales (from external customers):
Net Sales	$ 597.3	$ 196.8	$ 1,807.3	$ 569.6
Adjusted EBITDA:
Operating profit	31.3	23.3	77.5	32.9
Adjusted EBITDA	115.1	52.4	413.2	146.5
Performance Materials [Member]
Net Sales (from external customers):
Net Sales	179.7	196.8	541.6	569.6
Adjusted EBITDA:
Operating profit	54.5	52.4	156.9	146.5
Graphic Solutions [Member]
Net Sales (from external customers):
Net Sales	417.6	0	1,265.7	0
Adjusted EBITDA:
Operating profit	$ 60.6	$ 0	$ 256.3	$ 0

Segment Information (Details 2)

Segment Information (Details 2) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2015	Sep. 30, 2014
Segment Reporting [Abstract]
Adjusted EBITDA	$ 115.1	$ 52.4	$ 413.2	$ 146.5
Interest expense	(54.3)	(8.1)	(147.2)	(23.8)
Depreciation and amortization expense	(62)	(18.9)	(176.3)	(57.2)
Restructuring and related expenses	(4.5)	(0.6)	(18.2)	(1)
Manufacturer's profit in inventory adjustment	(1.3)	0	(58)	(12)
Acquisition transaction costs	(15)	(7.7)	(70.4)	(18.4)
Non-cash fair value adjustment to contingent consideration	(2.7)	(2.3)	(6.3)	(26.1)
Legal settlement	0	0	16	0
Acquisition put option settlement	0	0	3	0
Foreign exchange loss on foreign denominated external and internal debt	(33)	(2.6)	(26.8)	(2.6)
Fair value loss on foreign exchange forward contract	(48.1)	0	(48.1)	0
Other income	1.6	0.1	4	0.5
Net (loss) income before income taxes and non-controlling interest	(104.2)	12.3	(115.1)	5.9
Income tax (expense) benefit	(17.6)	1.6	(42)	3.6
Net income attributable to the non-controlling interests	(0.5)	(2)	(4)	(5.4)
Net (loss) income attributable to stockholders	$ (122.3)	$ 11.9	$ (161.1)	$ 4.1

Subsequent Events (Details)

Subsequent Events (Details) £ / shares in Units, $ / shares in Units, € in Millions

Oct. 27, 2015USD ($)$ / sharesshares

Jul. 13, 2015£ / shares

Feb. 25, 2015shares

Feb. 13, 2015USD ($)shares

Mar. 31, 2016USD ($)

Nov. 10, 2015USD ($)

Nov. 05, 2015GBP (£)$ / collar

Oct. 28, 2015USD ($)$ / €

Oct. 28, 2015EUR (€)$ / €

Sep. 30, 2015$ / shares

Sep. 30, 2015shares

Sep. 30, 2015MXN / $

Sep. 30, 2015BRL / $

Dec. 31, 2014shares

Subsequent Event [Line Items]

Common shares outstanding (in shares) | shares

210,879,597

182,066,980

Conversion price (in usd per share) | $ / shares

$ 27.14

Number of pence per ordinary share of acquiree | £ / shares

£ 0.503

Foreign currency exchange rate

0.0591

0.2527

Arysta [Member]

Subsequent Event [Line Items]

Total Consideration

$ 3,502,100,000

Maximum share conversion (in shares) | shares

22,107,590

22,107,590

Volume weighted average price period

10 days

Arysta [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Conversion price (in usd per share) | $ / shares

$ 27.14

Maximum share conversion (in shares) | shares

22,107,590

Maximum share conversion amount

$ 600,000,000

Volume weighted average price period

10 days

Aggregate dividend payable

$ 4,000,000

Alent [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Foreign currency exchange rate | $ / €

1.09

1.09

U.S. Dollar Denominated Term Loans [Member] | Alent [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Long term debt

$ 1,045,000,000

Euro Denominated Term Loans [Member] | Alent [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Long term debt

$ 330,000,000

€ 300

Senior Notes [Member] | Senior Notes Due 2021 10.375 Percent [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Debt Instrument, Face Amount

$ 500,000,000

Debt Instrument, Interest Rate, Stated Percentage

10.375%

Revolving Credit Facility [Member]

Subsequent Event [Line Items]

Revolving credit facility

$ 163,000,000

Revolving Credit Facility, Multi Currency [Member]

Subsequent Event [Line Items]

Revolving credit facility

$ 163,000,000

Designated as Hedging Instrument [Member] | Foreign Exchange Option [Member] | Alent [Member] | Subsequent Event [Member]

Subsequent Event [Line Items]

Collar price | $ / collar

1.56

Derivative, Floor Price | $ / collar

1.52

Debt amount affected by interest rate swap | £

£ 530,000,000

Scenario, Forecast [Member] | OMG [Member]

Subsequent Event [Line Items]

Total Consideration

$ 367,000,000